



**BlueCross BlueShield
of Vermont**

An Independent Licensee of the Blue Cross and Blue Shield Association.

Investigational Services and Procedures Corporate Medical Policy

File Name: Investigational Services and Procedures
File Code: 10.01.VT204
Origination: 09/2016
Last Review: 09/2023
Next Review: 11/2023
Effective Date: 10/01/2023 (Adaptive Maintenance Only)

Description

Attachment (I) outlines current services and/or procedure(s) considered to be investigational by Blue Cross Blue Shield of Vermont (BCBSVT).

Definition of Investigational

“Experimental or Investigational Services” means health care items or services that are either not generally accepted by informed health care providers in the United States as effective in treating a condition, illness, or diagnosis for which their use is proposed, or are not proven by medical or scientific evidence to be effective in treating a condition, illness, or diagnosis.

Technologies are assessed using the following criteria. Any technology that fails to meet ALL the following criteria is considered to be “Investigational”:

1. The technology must have final approval from the appropriate governmental regulatory bodies.
 - This criterion applies to drugs, biological products, devices and any other product or procedure that must have final approval to market from the U.S. Food and Drug Administration (FDA) or any other federal governmental body with authority to regulate the use of the technology.
 - Any approval that is granted as an interim step in the U.S. Food and Drug Administration’s or any other federal governmental body’s regulatory process is not sufficient.
 - The indications for which the technology is approved need not be the same as those which the (BCBSVT) Medical Policy Committee is evaluating.
2. The scientific evidence must permit conclusions concerning the effect of the technology

on health outcomes.

- The evidence should consist of well-designed and well-conducted investigations published in peer-reviewed journals. The quality of the body of studies and the consistency of the results are considered in evaluating the evidence.
 - The evidence should demonstrate that the technology can measure or alter the physiological changes related to a disease, injury, illness, or condition. In addition, there should be evidence, or a convincing argument based on established medical facts that such measurement or alteration affects health outcomes.
3. The technology must improve the net health outcome.
- The technology's beneficial effects on health outcomes should outweigh any harmful effects on health outcomes.
4. The technology must be as beneficial as any established alternatives.
- The technology should improve the net health outcome as much as, or more than, established alternatives.
5. The improvement must be attainable outside the investigational settings.
- When used under the usual conditions of medical practice, the technology should be reasonably expected to satisfy Criteria #3 and #4.

In reviewing the above criteria, the BCBSVT Medical Policy Committee will consider physician specialty society recommendations, the view of prudent medical practitioners practicing in relevant clinical areas and any other relevant factors.

Policy

The following is a list of current services and/or procedure(s) which are considered investigational.

Coding Information

[Attachment I](#)

Policy Implementation/Update information

| | |
|---------|--|
| 06/2020 | Policy new Format |
| 10/2020 | Coding Updates effective 10/01/2020 Medical Policy: Added codes: 0097U, 0107U, 82239, 82272, 82274, 82542, 82656, 82710, 82715, 82725, 83520, 83630, 83986, 83993, 84311, 87045, 87046, 87075, 87102, 87177, 87209, 87328, 87329, 87336, 89160, 89161, 89240 ARE CONSIDERED INVESTIGATIONAL WITH THE FOLLOWING DIAGNOSES CODES: A04.8, A04.9, K58.0, K58.1, K58.2, K58.8, K58.9, K59.8, K63.9, K90.89. |

| | |
|---------|---|
| | Coding Updates effective 10/01/2020 via Adaptive Maintenance Cycle: Added codes: 0016M, 0203U, 0204U, 0205U, 0206U, 0207U, 0208U, 0209U, 0211U, 0216U, 0217U, 0218U, 0219U, 0220U, 0225U, K1006, K1007, K1010, K1011, K1012, Q4249, Q4250, Q4254, Q4255. |
| 01/2021 | Coding Updates effective 01/01/2021 Adaptive Maintenance Cycle: Changed effective date to 01/01/2021 Removed Codes 38230, 83993, 90694 Updated Codes 82172 & 84181 to Investigational for All diagnoses Updated Codes 64910, 64911, 64912, 64913 as Investigational with dx codes C61, N52.0-N52.9 Added codes 0227U, 0228U, 0229U, 0620T, 0621T, 0622T, 0623T, 0624T, 0625T, 0626T, 0627T, 0628T, 0629T, 0630T, 0631T, 0632T, 0633T, 0634T, 0635T, 0636T, 0637T, 0638T, 0639T, 22869, 22870 30468, 55880, 57465, 81514, 92229, C1825, C9771, C9772, C9773, C9774, C9775 Deleted codes 0400T, 0401T Removed codes 38206, 38230, 38241 codes require PA |
| 04/2021 | Coding Updates effective 04/01/2021 Adaptive Maintenance Cycle: Added codes: C9776, C9777, J3490, K1016, K1017, K1018, K1019, K1020, S1091, 0242U, 0243U, 0244U, 0247U. Removed codes: K1010, K1011, K1012, 64451, 78803, 78830, 78831, 78832, 78835 |
| 05/2021 | Coding Update effective 05/01/2021: Added codes 81518, 0045U, 0153U. |
| 07/2021 | Coding Updates effective 07/01/2021: 0248U, 0249U, 0250U, 0251U, 0252U, 0253U, 0640T, 0641T, 0642T, 0643T, 0645T, 0646T, 0647T, 0648T, 0649T, 0652T, 0653T, 0654T, 0655T, 0656T, 0657T, 0658T, 0659T, 0660T, 0661T, 0664T, 0665T, 0666T, 0667T, 0668T, 0669T, 0670T, A9593, A9594, G0327, 58674, 90626, 90627, 90671, 90677, 90758, C1761 |
| 08/2021 | Coding Updates effective 08/01/2021: Added codes E1700, E1701, E1702 |
| 09/2021 | Coding update effective 09/01/2021: Removed code 53854 |
| 10/2021 | Coding update effective 10/01/2021: Added Codes 0255U, 0258U, 0259U 0260U, 0261U, 0262U, 0263U, 0264U, 0266U, 0267U, 0279U, 0280U, 0281U, 0282U, 0283U, 0284U, 0018M, Deleted code 0139U. Revised 0051U descriptor. Added HCPCS Codes: C1831, C9780, K1023, K1024, K1025, K1026, Q4251, Q4252, Q4253 |
| 11/2021 | Coding update effective 11/01/2021 (To Align Corporate Bioengineered Skin Medical Policy Table): Added codes C9354, C9356, C9358, C9360, C9363, C9364, Q4103, Q4104, Q4110, Q4111, Q4112, Q4113, Q4115, Q4117, Q4118, Q4121, Q4123, Q4124, Q4125, Q4126, Q4127, Q4130, Q4134, Q4135, Q4136, Q4141, Q4142, Q4143, Q4146, Q4147, Q4149, Q4152, Q4158, Q4161, Q4164, Q4165, Q4166, Q4167, Q4179, Q4182, Q4193, Q4196, Q4200, Q4202, Q4203, Q4222. Removed codes: Q4185, Q4189, Q4192, Q4249, Q4250, Q4254, Q4255. |
| 12/2021 | Coding update effective 12/01/2021: Added code G9143 |
| 12/2021 | Coding Update Effective 01/01/2022 (Adaptive Maintenance Cycle): Deleted the following codes: 0548T, 0549T, 0550T, 0551T, C9752, C9753, 95943, 0208U Codes Added: 33370, 42975, 43497, 53451, 53452, 53453, 53454, 61736, 61737, 64628, 64629, 81560, 90759. Added codes PLA: 0285U, 0288U, 0289U, 0290U, 0291U, 0292U, 0293U, 0294U, 0295U, 0296U, 0297U, 0298U, 0299U, 0300U, 0303U, 0304U, 0305U. Added codes CAT III: 0672T, 0673T, 0674T, 0675T, 0676T, 0677T, 0678T, 0679T, 0680T, 0681T, 0682T, 0683T, 0684T, 0685T, 0686T, 0687T, 0688T, 0689T, 0690T, 0691T, 0693T, 0694T, 0695T, 0696T, 0697T, 0698T, |

| | |
|---------|--|
| | 0700T, 0701T, 0702T, 0703T, 0704T, 0705T, 0706T, 0707T, 0708T, 0709T, 0710T, 0711T, 0712T, 0713T. Added the following HCPCS Codes: A2001, A2002, A2004, A2005, A2006, A2007, A2008, A2009, A2010, C1832, C1833, G0465, Q4199. Removed codes: 0030U, 0032U, 0033U, 0173U, 0175U, 90677. |
| 04/2022 | Coding Update Effective 04/01/2022 (Adaptive Maintenance Cycle): A2003 deleted code never became effective 01/01/2021. (0)097U deleted. Added codes: 0306U, 0307U, 0308U, 0309U, 0310U, 0311U, 0312U, 0313U, 0314U, 0315U, 0316U, 0317U, 0318U, 0319U, 0320U, 0321U, 0322U. A2013, A9291, C9781, K1028, K1029, K1030, K1031, K1032, K1033. Removed code J3490 per Ketamine Medical Policy effective 04/01/2022. |
| 05/2022 | Coding Update Effective 05/01/2022 (Investigational Medical Policy Reconciliation): Codes removed: A4641, A4642, A9500, A9502, A9520, A9541, A9568, A9572, A9582 may be eligible for benefit approved by AIM or BCBSVT. Codes removed: J9035, 15788, 15789, 15792, 15793, 17000, 17003, 17004, 30520, 17106, 17107, 17108, 82656, 83630, 90677 effective: 01/01/2022), 97032 may be eligible for services based on current standards of care. Codes removed: G0259, L8603*, L8605*, L8606*, L8684, S8080, 0026U, 0097U, 0107U, 0278T, 15824, 15826, 30130, 30140, 31626, 34701, 34702, 34703, 34704, 34705, 34706, 34707, 34708, 36012, 37241, 38242, 43201, 43210, 43212, 43257, 51715, 64590, 64595, 64632, 64640, 64716, 64722, 64771, 64772, 64910, 64911, 64912, 64913, 76940, 78195, 78800, 78801, 78802, 78804, 82239, 82272, 82274, 82397, 82542, 82652, 82710, 82715, 82725, 83520, 83698, 83986, 84311, 86141, 86304, 87045, 87046, 87075, 87102, 87177, 87209, 87328, 87329, 87336, 89160, 89240, 92229, 93895, 95812, 95813, 95816, 95819, 95921, 95922, 95923, 95924, 96904 codes require prior approval. Removed codes: E0748, E0749, J3490, L8680, L8681, L8682, L8683, L8685, L8686, L8687, L8688, L8689, Q4168, Q4185, Q4189, Q4192, S3852, 0029U, 0156U, 0173U, 0175U, 0278U, 0394T, 15780, 15781, 15782, 15783, 20974, 20975, 61885, 61886, 64553, 64568, 64569, 64570, 67900, 75571, 81226, 81291, 81313, 81400, 81401, 81403, 81406, 81407, 81415, 81416, 81417, 81439, 81490, 81493, 81500, 81503, 81504, 81535, 81536, 81538, 81540, 81595, 95980, 95981, 95982 codes always required prior approval. Changed the following codes to be investigational for all diagnoses: A9584, E0740, E0761, E0769, G0166, G0295, G0329, G9147, S3722, 0003U, 0101T, 0102T, 0207T, 0278T, 0330T, 0332T, 0338T, 0339T, 0397T, 0421T, 0424T, 0425T, 0426T, 0441T, 0563T, 28890, 33548, 43206, 43252, 43284, 43285, 43647, 43648, 43881, 43882, 46707, 47371, 47381, 47383, 62263, 62264, 64505, 77085, 77086, 82523, 83006, 83695, 84080, 85384, 86352, 88375, 95957, 97610, 98922. Added new codes: C1825, C9359, C9362, E0746, G9143, S8130, S8131, 0651T, 64575 investigational for all diagnoses. Removed codes: G0281, G0282, V5095, 90876, 97014 codes are considered non-covered. Removed code S2080 code considered not medically necessary. Removed codes 31627 & 57465 not medically necessary per payment policy CPP_04. Added codes to as investigation but have been investigational per applicable medical policy: E0762, E0764, M0076, P9020, S8040, 0232T, 0355T, 41512, 64585, 83937, 91111, 92548, 92145, 92572, 92576, 93701, 95803, 96000, 96001, 96002, 96003, 96004, 97799. Codes deleted: A9599, C9750, 0355T, 0399T, 0406T, 0407T, 30660, 30661, 61632, 98922. |
| 06/2022 | Removed codes 0116U & 0117U Effective: 06/01/2022 Added code P2031 Effective: 06/01/2022, Added COVID-19 |

| | |
|---------|---|
| | Monoclonal Antibodies & Administration codes: M0240, M0241, M0243, M0244, M0245, M0246, Q0240, Q0243, Q0244, Q0245 Effective:01/24/2022. Added COVID-19 Monoclonal Antibodies & Administration codes: M0247, M0248, Q0247 Effective: 04/05/2022. |
| 06/2022 | Coding Update Effective 07/01/2022 (Adaptive Maintenance Cycle): Revised code descriptor 0229U. Removed code 83880 off- cycle map as medically necessary. Removed codes 0648T & 0649T from NIV to requiring PA add to PA CAT Code 'MQM' per medical policy changes to be reviewed by AIM 07/01/2022. Removed code 42975, 87426 & C9776 - medically necessary. Removed codes 90626 & 90627 FDA approved covered travel. Removed code 90759 FDA approved - preventive grid. Added codes: 90584, 0714T, 0715T, 0716T, 0717T, 0718T, 0719T, 0720T, 0721T, 0722T, 0723T, 0724T, 0725T, 0726T, 0727T, 0728T, 0729T, 0730T, 0731T, 0732T, 0733T, 0734T, 0735T, 0736T, 0737T, 0323U, 0324U, 0325U, 0328U, 0329U, 0330U, 0331U A9601, Q4259, Q4260, Q4261. Re-sequenced code 0330T. |
| 09/2022 | Coding Update Effective 10/01/2022 (Adaptive Maintenance Cycle): Added Codes Q1005, S0596, V2787, V2788, added to the Investigational policy the codes are considered investigational per the Vision Corporate Medical Policy. Removed codes 95976, 95977 & 58674 the codes will require prior approval. Removed code 84181 as investigational. Added the following PLA codes: 0332U, 0333U, 0334U, 0335U, 0336U, 0337U, 0338U, 0339U, 0340U, 0341U, 0342U, 0343U, 0344U, 0345U, 0346U, 0347U, 0348U, 0349U, 0350U, 0351U, 0352U as investigational. Added codes: A2014, A2015, A2016, A2017, A2018, A4596, C1834. |
| 11/2022 | Effective 11/01/2022: Removed codes: 0037U & 0129U from investigational to requiring prior approval. Removed codes 85384 & 85385 from investigational to medically necessary. Removed codes 0224U & 0225U from investigational to eligible at zero-cost share COVID-19. |
| 12/2022 | Effective 01/01/2023 (Adaptive Cycle Maintenance): Deleted Codes: 0312T, 0313T, 0314T, 0315T, 0316T, 0317T, 0514T, 0702T, 0703T. C1841, G2170, G2171. Revised Codes: 0733T, 0734T. Added codes as Investigational: 22860, 30469, 36836, 36837, 43290, 43291, 77089, 77090, 77091, 77092, 81418, 81449, 81451, 81456, 90678, 98978, 0738T, 0739T, 0740T, 0741T, 0742T, 0743T, 0744T, 0745T, 0746T, 0747T, 0748T, 0749T, 0750T, 0751T, 0752T, 0753T, 0754T, 0755T, 0756T, 0757T, 0758T, 0759T, 0760T, 0761T, 0762T, 0763T, 0764T, 0765T, 0766T, 0767T, 0768T, 0769T, 0770T, 0771T, 0772T, 0773T, 0774T, 0775T, 0776T, 0777T, 0778T, 0779T, 0780T, 0781T, 0782T, 0783T, 0355U, 0356U, 0357U, 0358U, 0359U, 0360U, 0361U, 0362U, 0363U, C1747, C1826, C1827, C7501, C7502, Q4262, Q4263, Q4264. Removed code as Investigational: 0421T. |
| 01/2023 | Policy reviewed removed codes 0202U & 0223U from investigational to eligible at zero cost share COVID-19 effective 11/01/2022. |
| 02/2023 | Policy reviewed removed code 81518 from investigational to requiring prior approval effective 03/01/2023. |
| 03/2023 | Effective 04/01/2023 (Adaptive Maintenance Cycle): C1834, 0324U, 0325U codes deleted. Code 0095U descriptor revised. Removed codes 0449T, 0450T, 90758 from investigational to medically necessary. Added codes: 0364U, 0365U, 0366U, 0367U, 0369U, 0370U, 0371U, 0372U, 0374U, 0375U, 0376U, 0377U, 0378U, 0379U, 0380U, 0384U, 0385U, 0386U, A2019, A2020, A2021, A4341, A4342, A4560, A6590, A6591, A7049, E0677, E0711, E1905, L8678, Q4265, Q4266, Q4267, Q4268, Q4269, Q4270, Q4271 as investigational to the coding table |

| | |
|---------|--|
| 03/2023 | Effective 06/01/2023 Medical Policy Review- Added codes: E1806, E1811, E1816, E1818, E1821, E1831, E1841 |
| 06/2023 | Effective 07/01/2023 (Adaptive Maintenance Cycle): Removed codes: 83721, 90671. Deleted Code: 0053U. Added Codes: 0387U, 0389U, 0390U, 0391U, 0392U, 0393U, 0394U, 0395U, 0398U, 0399U, 0400U, 0401U, 0791T, 0792T, 0793T, 0794T, 0795T, 0796T, 0797T, 0798T, 0799T, 0800T, 0801T, 0802T, 0803T, 0804T, 0805T, 0806T, 0807T, 0808T, 0809T, C9150, C9784, C9785, C9786, C9787, Q4272, Q4273, Q4274, Q4275, Q4276, Q4277, Q4278, Q4280, Q4281, Q4282, Q4283, Q4284. Added Codes (COVID-19): Refer to dates in table: 91300, 91301, 91303, 91305, 91306, 91307, 91308, 91309, 91311, 0001A, 0002A, 0003A, 0004A, 0011A, 0012A, 0013A, 0031A, 0034A, 0051A, 0052A, 0053A, 0054A, 0064A, 0071A, 0072A, 0073A, 0074A, 0081A, 0082A, 0083A, 0091A, 0092A, 0093A, 0094A, 0111A, 0112A, M0220, M0221, M0222, M0223, M0240, M0241, M0243, M0244, M0245, M0246, M0247, M0248, Q0220, Q0221, Q0222, Q0240, Q0243, Q0244, Q0245, Q0247. |
| 09/2023 | Effective 10/01/2023 (Adaptive Maintenance Cycle): Revised: 0362U, 0389U, 0401U, K1004, K1028. Deleted: 0357U, 0386U. Removed: 90678 code medically necessary. Added: 0019M, 0071T, 0072T, 0403U, 0404U, 0405U, 0406U, 0407U, 0408U, 0410U, 0411U, 0412U, 0413U, 0414U, 0415U, 0416U, 0417U, 0418U, 0419U, A2022, A2023, A2024, A2025, A9268, A9269, A9292, A9573, A9603, A9697, C9788, C9790, C9791, C9792, E0490, E0491, K1036, Q4285, Q4286. |

Eligible Providers

Qualified healthcare professionals practicing within the scope of their license(s).

Approved by BCBSVT Medical Directors

Tom Weigel, MD, MBA
Vice President and Chief Medical Officer

Tammaji P. Kulkarni, MD
Senior Medical Director

Attachment I

| CPT®/HCPCS Code | CPT®/HCPCS Code Description | Instructions |
|-----------------|---|-----------------|
| A2001 | InnovaMatrix AC, per sq cm | Investigational |
| A2002 | Mirrugen Advanced Wound Matrix, per sq cm | Investigational |
| A2004 | XCelliStem, per sq cm | Investigational |
| A2005 | Microlyte Matrix, per sq cm | Investigational |

| | | |
|--------------|---|-----------------|
| A2006 | NovoSorb SynPath dermal matrix, per sq cm | Investigational |
| A2007 | Restrata, per sq cm | Investigational |
| A2008 | TheraGenesis, per sq cm | Investigational |
| A2009 | Symphony, per sq cm | Investigational |
| A2010 | Apis, per sq cm | Investigational |
| A2013 | Innovamatrix FS, per sq cm | Investigational |
| A2014 | Omeza collagen matrix, per 100 mg | Investigational |
| A2015 | Phoenix wound matrix, per square centimeter | Investigational |
| A2016 | Permeaderm b, per square centimeter | Investigational |
| A2017 | Permeaderm glove, each | Investigational |
| A2018 | Permeaderm c, per square centimeter | Investigational |
| A2019 | Kerecis omega3 marigen shield, per square centimeter | Investigational |
| A2020 | Ac5 advanced wound system (ac5) | Investigational |
| A2021 | Neomatrix, per square centimeter | Investigational |
| A2022 | Innovaburn or innovamatrix xl, per square centimeter | Investigational |
| A2023 | Innovamatrix pd, 1 mg | Investigational |
| A2024 | Resolve matrix, per square centimeter | Investigational |
| A2025 | Miro3d, per cubic centimeter | Investigational |
| A4341 | Indwelling intraurethral drainage device with valve, patient inserted, replacement only, each | Investigational |
| A4342 | Accessories for patient inserted indwelling intraurethral drainage device with valve, replacement only, each | Investigational |
| A4560 | Neuromuscular electrical stimulator (nmes), disposable, replacement only | Investigational |
| A4563 | Rectal control system for vaginal insertion, for long term use, includes pump and all supplies and accessories, any type each | Investigational |
| A4575 | Topical hyperbaric oxygen chamber, disposable | Investigational |
| A4596 | Cranial electrotherapy stimulation (ces) system supplies and accessories, per month | Investigational |
| A6590 | External urinary catheters; disposable, with wicking material, for use with suction pump, per month | Investigational |

| | | |
|--------------|--|-----------------|
| A6591 | External urinary catheter; non-disposable, for use with suction pump, per month | Investigational |
| A7049 | Expiratory positive airway pressure intranasal resistance valve | Investigational |
| A9268 | Programmer for transient, orally ingested capsule | Investigational |
| A9269 | Programable, transient, orally ingested capsule, for use with external programmer, per month | Investigational |
| A9291 | Prescription digital behavioral therapy, FDA-cleared, per course of treatment | Investigational |
| A9292 | Prescription digital visual therapy, software-only, fda cleared, per course of treatment | Investigational |
| A9507 | Indium In-111 capromab pendetide, diagnostic, per study dose, up to 10 millicuries | Investigational |
| A9573 | Injection, gadopichlenol, 1 ml | Investigational |
| A9584 | Iodine I-123 ioflupane, diagnostic, per study dose, up to 5 mCi | Investigational |
| A9586 | Florbetapir F18, diagnostic, per study dose, up to 10 mCi | Investigational |
| A9593 | Gallium Ga-68 PSMA-11, diagnostic, (UCSF), 1 mCi | Investigational |
| A9594 | Gallium Ga-68 PSMA-11, diagnostic, (UCLA), 1 mCi | Investigational |
| A9601 | Flortaucipir f 18 injection, diagnostic, 1 millicurie | Investigational |
| A9603 | Injection, pafolacianine, 0.1 mg | Investigational |
| A9697 | Injection, carboxydextran-coated superparamagnetic iron oxide, per study dose | Investigational |
| C1734 | Orthopedic/device/drug matrix for opposing bone-to-bone or soft tissue-to bone (implantable) | Investigational |
| C1747 | Endoscope, single-use (i.e. disposable), urinary tract, imaging/illumination device (insertable) | Investigational |
| C1761 | Catheter, transluminal intravascular lithotripsy, coronary | Investigational |
| C1821 | Interspinous process distraction device (implantable) | Investigational |

| | | |
|--------------|--|-----------------|
| C1823 | Generator, neurostimulator (implantable), nonrechargeable, with transvenous sensing and stimulation leads | Investigational |
| C1825 | Generator, neurostimulator (implantable), nonrechargeable with carotid sinus baroreceptor stimulation lead(s) | Investigational |
| C1826 | Generator, neurostimulator (implantable), includes closed feedback loop leads and all implantable components, with rechargeable battery and charging system | Investigational |
| C1827 | Generator, neurostimulator (implantable), non-rechargeable, with implantable stimulation lead and external paired stimulation controller | Investigational |
| C1831 | Personalized, anterior and lateral interbody cage (implantable) | Investigational |
| C1832 | Autograft suspension, including cell processing and application, and all system components | Investigational |
| C1833 | Monitor, cardiac, including intracardiac lead and all system components (implantable) | Investigational |
| C2596 | Probe, image guided, robotic, waterjet ablation | Investigational |
| C2614 | Probe, percutaneous lumbar discectomy | Investigational |
| C7501 | Percutaneous breast biopsies using stereotactic guidance, with placement of breast localization device(s) (eg, clip, metallic pellet), when performed, and imaging of the biopsy specimen, when performed, all lesions unilateral and bilateral (for single lesion biopsy, use appropriate code) | Investigational |

| | | |
|--------------|---|-----------------|
| C7502 | Percutaneous breast biopsies using magnetic resonance guidance, with placement of breast localization device(s) (eg, clip, metallic pellet), when performed, and imaging of the biopsy specimen, when performed, all lesions unilateral or bilateral (for single lesion biopsy, use appropriate code) | Investigational |
| C8937 | Computer-aided detection, including computer algorithm analysis of breast MRI image data for lesion detection/characterization, pharmacokinetic analysis, with further physician review for interpretation (list separately in addition to code for primary procedure) | Investigational |
| C9150 | Xenon xe-129 hyperpolarized gas, diagnostic, per study dose | Investigational |
| C9354 | Acellular pericardial tissue matrix of nonhuman origin (Veritas), per sq cm | Investigational |
| C9356 | Tendon, porous matrix of cross-linked collagen and glycosaminoglycan matrix (TenoGlide Tendon Protector Sheet), per sq cm | Investigational |
| C9358 | Dermal substitute, native, nondenatured collagen, fetal bovine origin (SurgiMend Collagen Matrix), per 0.5 sq cm | Investigational |
| C9359 | Porous purified collagen matrix bone void filler (Integra Mozaik Osteoconductive Scaffold Putty, Integra OS Osteoconductive Scaffold Putty), per 0.5 cc | Investigational |
| C9360 | Dermal substitute, native, nondenatured collagen, neonatal bovine origin (SurgiMend Collagen Matrix), per 0.5 sq cm | Investigational |
| C9362 | Porous purified collagen matrix bone void filler (Integra Mozaik Osteoconductive Scaffold Strip), per 0.5 cc | Investigational |
| C9363 | Skin substitute (Integra Meshed Bilayer Wound Matrix), per sq cm | Investigational |

| | | |
|--------------|--|-----------------|
| C9364 | Porcine implant, Permacol, per sq cm | Investigational |
| C9751 | Bronchoscopy, rigid or flexible, transbronchial ablation of lesion(s) by microwave energy, including fluoroscopic guidance, when performed, with computed tomography acquisition(s) and 3D rendering, computer-assisted, image-guided navigation, and endobronchial ultrasound (EBUS) guided transtracheal and/or transbronchial sampling (e.g., aspiration[s]/biopsy[ies]) and all mediastinal and/or hilar lymph node stations or structures and therapeutic intervention(s) | Investigational |
| C9758 | Blind procedure for NYHA Class III/IV heart failure; transcatheter implantation of interatrial shunt including right heart catheterization, transesophageal echocardiography (TEE)/intracardiac echocardiography (ICE), and all imaging with or without guidance (e.g., ultrasound, fluoroscopy), performed in an approved investigational device exemption (IDE) study | Investigational |
| C9759 | Transcatheter intraoperative blood vessel microinfusion(s) (e.g., intraluminal, vascular wall and/or perivascular) therapy, any vessel, including radiological supervision and interpretation, when performed | Investigational |

| | | |
|--------------|---|-----------------|
| C9760 | Nonrandomized, nonblinded procedure for NYHA Class II, III, IV heart failure; transcatheter implantation of interatrial shunt, including right and left heart catheterization, transeptal puncture, transesophageal echocardiography (TEE)/intracardiac echocardiography (ICE), and all imaging with or without guidance (e.g., ultrasound, fluoroscopy), performed in an approved investigational device exemption (IDE) study | Investigational |
| C9762 | Cardiac magnetic resonance imaging for morphology and function, quantification of segmental dysfunction; with strain imaging | Investigational |
| C9763 | Cardiac magnetic resonance imaging for morphology and function, quantification of segmental dysfunction; with stress imaging | Investigational |
| C9764 | Revascularization, endovascular, open or percutaneous, lower extremity artery(ies), except tibial/peroneal; with intravascular lithotripsy, includes angioplasty within the same vessel(s), when performed | Investigational |
| C9765 | Revascularization, endovascular, open or percutaneous, lower extremity artery(ies), except tibial/peroneal; with intravascular lithotripsy, and transluminal stent placement(s), includes angioplasty within the same vessel(s), when performed | Investigational |
| C9766 | Revascularization, endovascular, open or percutaneous, lower extremity artery(ies), except tibial/peroneal; with intravascular lithotripsy and atherectomy, includes angioplasty within the same vessel(s), when performed | Investigational |

| | | |
|--------------|---|-----------------|
| C9767 | Revascularization, endovascular, open or percutaneous, lower extremity artery(ies), except tibial/peroneal; with intravascular lithotripsy and transluminal stent placement(s), and atherectomy, includes angioplasty within the same vessel(s), when performed | Investigational |
| C9771 | Nasal/sinus endoscopy, cryoablation nasal tissue(s) and/or nerve(s), unilateral or bilateral | Investigational |
| C9772 | Revascularization, endovascular, open or percutaneous, tibial/peroneal artery(ies), with intravascular lithotripsy, includes angioplasty within the same vessel(s), when performed | Investigational |
| C9773 | Revascularization, endovascular, open or percutaneous, tibial/peroneal artery(ies); with intravascular lithotripsy, and transluminal stent placement(s), includes angioplasty within the same vessel(s), when performed | Investigational |
| C9774 | Revascularization, endovascular, open or percutaneous, tibial/peroneal artery(ies); with intravascular lithotripsy and atherectomy, includes angioplasty within the same vessel(s), when performed | Investigational |
| C9775 | Revascularization, endovascular, open or percutaneous, tibial/peroneal artery(ies); with intravascular lithotripsy and transluminal stent placement(s), and atherectomy, includes angioplasty within the same vessel(s), when performed | Investigational |
| C9777 | Esophageal mucosal integrity testing by electrical impedance, transoral, includes esophagoscopy or esophagogastroduodenoscopy | Investigational |

| | | |
|--------------|--|-----------------|
| C9780 | Insertion of central venous catheter through central venous occlusion via inferior and superior approaches (e.g., inside-out technique), including imaging guidance | Investigational |
| C9781 | Arthroscopy, shoulder, surgical; with implantation of subacromial spacer (e.g., balloon), includes debridement (e.g., limited or extensive), subacromial decompression, acromioplasty, and biceps tenodesis when performed | Investigational |
| C9784 | Gastric restrictive procedure, endoscopic sleeve gastropasty, with esophagogastroduodenoscopy and intraluminal tube insertion, if performed, including all system and tissue anchoring components | Investigational |
| C9785 | Endoscopic outlet reduction, gastric pouch application, with endoscopy and intraluminal tube insertion, if performed, including all system and tissue anchoring components | Investigational |
| C9786 | Echocardiography image post processing for computer aided detection of heart failure with preserved ejection fraction, including interpretation and report | Investigational |
| C9787 | Gastric electrophysiology mapping with simultaneous patient symptom profiling | Investigational |
| C9788 | Opto-acoustic imaging, breast (including axilla when performed), unilateral, with image documentation, analysis and report, obtained with ultrasound examination | Investigational |
| C9790 | Histotripsy (ie, non-thermal ablation via acoustic energy delivery) of malignant renal tissue, including image guidance | Investigational |

| | | |
|--------------|---|-----------------|
| C9791 | Magnetic resonance imaging with inhaled hyperpolarized xenon-129 contrast agent, chest, including preparation and administration of agent | Investigational |
| C9792 | Blinded or nonblinded procedure for symptomatic new york heart association (nyha) class ii, iii, iva heart failure; transcatheter implantation of left atrial to coronary sinus shunt using jugular vein access, including all imaging necessary to intra procedurally map the coronary sinus for optimal shunt placement (e.g., tee or ice ultrasound, fluoroscopy), performed under general anesthesia in an approved investigational device exemption (ide) study) | Investigational |
| E0218 | Fluid circulating cold pad with pump, any type | Investigational |
| E0236 | Pump for water circulating pad | Investigational |
| E0490 | Power source and control electronics unit for oral device/appliance for neuromuscular electrical stimulation of the tongue muscle, controlled by hardware remote | Investigational |
| E0491 | Oral device/appliance for neuromuscular electrical stimulation of the tongue muscle, used in conjunction with the power source and control electronics unit, controlled by hardware remote, 90-day supply | Investigational |
| E0677 | Non-pneumatic sequential compression garment, trunk | Investigational |
| E0711 | Upper extremity medical tubing/lines enclosure or covering device, restricts elbow range of motion | Investigational |
| E0740 | Nonimplanted pelvic floor electrical stimulator, complete system | Investigational |
| E0746 | Electromyography (EMG), biofeedback device | Investigational |

| | | |
|--------------|--|-----------------|
| E0761 | Nonthermal pulsed high frequency radiowaves, high peak power electromagnetic energy treatment device | Investigational |
| E0762 | Transcutaneous electrical joint stimulation device system, includes all accessories | Investigational |
| E0764 | Functional neuromuscular stimulation, transcutaneous stimulation of sequential muscle groups of ambulation with computer control, used for walking by spinal cord injured, entire system, after completion of training program | Investigational |
| E0769 | Electrical stimulation or electromagnetic wound treatment device, not otherwise classified | Investigational |
| E0770 | Functional electrical stimulator, transcutaneous stimulation of nerve and/or muscle groups, any type, complete system, not otherwise specified | Investigational |
| E1700 | Jaw motion rehabilitation system | Investigational |
| E1701 | Replacement cushions for jaw motion rehabilitation system, package of 6 | Investigational |
| E1702 | Replacement measuring scales for jaw motion rehabilitation system, package of 200 | Investigational |
| E1801 | Static progressive stretch elbow device, extension and/or flexion, with or without range of motion adjustment, includes all components and accessories | Investigational |
| E1806 | Static progressive stretch wrist device, flexion and/or extension, with or without range of motion adjustment, includes all components and accessories | Investigational |
| E1811 | Static progressive stretch knee device, extension and/or flexion, with or without range of motion adjustment, includes all components and accessories | Investigational |
| E1816 | Static progressive stretch ankle device, flexion and/or extension, with or without range of motion adjustment, includes all components and accessories | Investigational |

| | | |
|--------------|--|-----------------|
| E1818 | Static progressive stretch forearm pronation/supination device, with or without range of motion adjustment, includes all components and accessories | Investigational |
| E1821 | Replacement soft interface material/cuffs for bi-directional static progressive stretch device | Investigational |
| E1831 | Static progressive stretch toe device, extension and/or flexion, with or without range of motion adjustment, includes all components and accessories | Investigational |
| E1841 | Static progressive stretch shoulder device, with or without range of motion adjustment, includes all components and accessories | Investigational |
| E1905 | Virtual reality cognitive behavioral therapy device (cbt), including pre-programmed therapy software | Investigational |
| G0166 | External counterpulsation, per treatment session | Investigational |
| G0255 | Current perception threshold/sensory nerve conduction test, (SNCT) per limb, any nerve | Investigational |
| G0276 | Blinded procedure for lumbar stenosis, percutaneous image-guided lumbar decompression (PILD) or placebo-control, performed in an approved coverage with evidence development (CED) clinical trial | Investigational |
| G0295 | Electromagnetic therapy, to one or more areas, for wound care other than described in G0329 or for other uses | Investigational |
| G0327 | Colorectal cancer screening; blood-based biomarker | Investigational |
| G0329 | Electromagnetic therapy, to one or more areas for chronic Stage III and Stage IV pressure ulcers, arterial ulcers, diabetic ulcers and venous stasis ulcers not demonstrating measurable signs of healing after 30 days of conventional care as part of a therapy plan of care | Investigational |

| | | |
|--------------|--|-----------------|
| G0465 | Autologous platelet rich plasma (PRP) for diabetic chronic wounds/ulcers, using an FDA-cleared device (includes administration, dressings, phlebotomy, centrifugation, and all other preparatory procedures, per treatment) | Investigational |
| G2000 | Blinded administration of convulsive therapy procedure, either electroconvulsive therapy (ECT, current covered gold standard) or magnetic seizure therapy (MST, noncovered experimental therapy), performed in an approved IDE-based clinical trial, per treatment session | Investigational |
| G9143 | Warfarin responsiveness testing by genetic technique using any method, any number of specimen(s) | Investigational |
| G9147 | Outpatient Intravenous Insulin Treatment (OIVIT) either pulsatile or continuous, by any means, guided by the results of measurements for: respiratory quotient; and/or, urine urea nitrogen (UUN); and/or, arterial, venous or capillary glucose; and/or potassium concentration | Investigational |
| K1001 | Electronic positional obstructive sleep apnea treatment, with sensor, includes all components and accessories, any type | Investigational |
| K1002 | Cranial electrotherapy stimulation (CES) system, includes all supplies and accessories, any type | Investigational |
| K1004 | Low frequency ultrasonic diathermy treatment device for home use | Investigational |
| K1006 | Suction pump, home model, portable or stationary, electric, any type, for use with external urine management system | Investigational |

| | | |
|--------------|--|-----------------|
| K1007 | Bilateral hip, knee, ankle, foot (HKAFO) device, powered, includes pelvic component, single or double upright(s), knee joints any type, with or without ankle joints any type, includes all components and accessories, motors, microprocessors, sensors | Investigational |
| K1016 | Transcutaneous electrical nerve stimulator for electrical stimulation of the trigeminal nerve | Investigational |
| K1017 | Monthly supplies for use of device coded at K1016 | Investigational |
| K1018 | External upper limb tremor stimulator of the peripheral nerves of the wrist | Investigational |
| K1019 | Monthly supplies for use of device coded at K1018 | Investigational |
| K1020 | Noninvasive vagus nerve stimulator | Investigational |
| K1023 | Distal transcutaneous electrical nerve stimulator, stimulates peripheral nerves of the upper arm | Investigational |
| K1024 | Nonpneumatic compression controller with sequential calibrated gradient pressure | Investigational |
| K1025 | Nonpneumatic sequential compression garment, full arm | Investigational |
| K1026 | Mechanical allergen particle barrier/inhalation filter, cream, nasal, topical | Investigational |
| K1028 | Power source and control electronics unit for oral device/appliance for neuromuscular electrical stimulation of the tongue, of the tongue muscles muscle controlled by phone application | Investigational |
| K1029 | Oral device/appliance for neuromuscular electrical stimulation of the tongue muscle, used in conjunction with the power source and control electronics unit, controlled by phone application, 90-day supply | Investigational |

| | | |
|--------------|--|---|
| K1030 | External recharging system for battery (internal) for use with implanted cardiac contractility modulation generator, replacement only | Investigational |
| K1031 | Nonpneumatic compression controller without calibrated gradient pressure | Investigational |
| K1032 | Nonpneumatic sequential compression garment, full leg | Investigational |
| K1033 | Nonpneumatic sequential compression garment, half leg | Investigational |
| K1036 | Supplies and accessories (e.g., transducer) for low frequency ultrasonic diathermy treatment device, per month | Investigational |
| L8608 | Miscellaneous external component, supply or accessory for use with the Argus II Retinal Prosthesis System | Investigational |
| L8678 | Electrical stimulator supplies (external) for use with implantable neurostimulator, per month | Investigational |
| M0076 | Prolotherapy | Investigational |
| M0220 | Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known SARS-CoV-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available COVID-19 vaccine is not recommended due to a history of severe adverse reaction to a COVID-19 vaccine(s) and/or COVID-19 vaccine component(s), includes injection and post administration monitoring | Investigational COVID-19 Effective:(01/26/2023) |

| | | |
|--------------|---|--|
| M0221 | Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known SARS-CoV-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available COVID-19 vaccine is not recommended due to a history of severe adverse reaction to a COVID-19 vaccine(s) and/or COVID-19 vaccine component(s), includes injection and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the COVID-19 public health emergency | Investigational COVID-19 Effective:(01/26/2023) |
| M0222 | Intravenous injection, bebtelovimab, includes injection and post administration monitoring | Investigational COVID-19 Effective:(11/30/2022) |
| M0223 | Intravenous injection, bebtelovimab, includes injection and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the COVID-19 public health emergency | Investigational COVID-19 Effective:(11/30/2022) |
| M0240 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab, includes infusion or injection and post administration monitoring, subsequent repeat doses | Investigational COVID-19 Effective:(01/24/2022) |

| | | |
|--------------|---|--|
| M0241 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab, includes infusion or injection, and post administration monitoring in the home or residence. This includes a beneficiary's home that has been made provider-based to the hospital during the covid-19 public health emergency, subsequent repeat doses | Investigational COVID-19 Effective:(01/24/2022) |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab, includes infusion or injection, and post administration monitoring | Investigational COVID-19 Effective:(01/24/2022) |
| M0244 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab, includes infusion or injection and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the COVID-19 public health emergency | Investigational COVID-19 Effective:(01/24/2022) |
| M0245 | Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring | Investigational COVID-19 Effective:(01/24/2022) |
| M0246 | Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the COVID-19 public health emergency | Investigational COVID-19 Effective:(01/24/2022) |
| M0247 | Intravenous infusion, sotrovimab, includes infusion and post administration monitoring | Investigational COVID-19 Effective:(04/05/2022) |

| | | |
|--------------|---|---|
| M0248 | Intravenous infusion, sotrovimab, includes infusion and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the COVID-19 public health emergency | Investigational COVID-19 Effective:(04/05/2022) |
| P2031 | Hair analysis (excluding arsenic) | Investigational |
| P9020 | Platelet rich plasma, each unit | Investigational |
| Q0220 | Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known SARS-CoV-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available COVID-19 vaccine is not recommended due to a history of severe adverse reaction to a COVID-19 vaccine(s) and/or COVID-19 vaccine component(s), 300 mg | Investigational COVID-19 Effective:(01/26/2023) |
| Q0221 | Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known SARS-CoV-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available COVID-19 vaccine is not recommended due to a history of severe adverse reaction to a COVID-19 vaccine(s) and/or COVID-19 vaccine component(s), 600 mg | Investigational COVID-19 Effective:(01/26/2023) |
| Q0222 | Injection, bebtelovimab, 175 mg | Investigational COVID-19 Effective:(11/30/2022) |
| Q0240 | Injection, casirivimab and imdevimab, 600 mg | Investigational COVID-19 Effective:(01/24/2022) |
| Q0243 | Injection, casirivimab and imdevimab, 2400 mg | Investigational COVID-19 Effective:(01/24/2022) |
| Q0244 | Injection, casirivimab and imdevimab, 1200 mg | Investigational COVID-19 Effective:(01/24/2022) |

| | | |
|-------|--|---|
| Q0245 | Injection, bamlanivimab and etesevimab, 2100 mg | Investigational COVID-19 Effective:(01/24/2022) |
| Q0247 | Injection, sotrovimab, 500 mg | Investigational COVID-19 Effective:(04/05/2022) |
| Q1005 | New technology, intraocular lens, category 5 as defined in Federal Register notice | Investigational |
| Q4103 | Oasis burn matrix, per sq cm | Investigational |
| Q4104 | Integra bilayer matrix wound dressing (BMWD), per sq cm | Investigational |
| Q4110 | PriMatrix, per sq cm | Investigational |
| Q4111 | GammaGraft, per sq cm | Investigational |
| Q4112 | Cymetra, injectable, 1 cc | Investigational |
| Q4113 | GRAFTJACKET XPRESS, injectable, 1 cc | Investigational |
| Q4115 | AlloSkin, per sq cm | Investigational |
| Q4117 | HYALOMATRIX, per sq cm | Investigational |
| Q4118 | MatriStem micromatrix, 1 mg | Investigational |
| Q4121 | TheraSkin, per sq cm | Investigational |
| Q4123 | AlloSkin RT, per sq cm | Investigational |
| Q4124 | OASIS ultra tri-layer wound matrix, per sq cm | Investigational |
| Q4125 | ArthroFlex, per sq cm | Investigational |
| Q4126 | MemoDerm, DermaSpan, TranZgraft or InteguPly, per sq cm | Investigational |
| Q4127 | Talymed, per sq cm | Investigational |
| Q4130 | Strattice TM, per sq cm | Investigational |
| Q4134 | HMatrix, per sq cm | Investigational |
| Q4135 | Mediskin, per sq cm | Investigational |
| Q4136 | E-Z Derm, per sq cm | Investigational |
| Q4141 | AlloSkin AC, per sq cm | Investigational |
| Q4142 | XCM biologic tissue matrix, per sq cm | Investigational |
| Q4143 | Repriza, per sq cm | Investigational |
| Q4146 | Tensix, per sq cm | Investigational |
| Q4147 | Architect, Architect PX, or Architect FX, extracellular matrix, per sq cm | Investigational |
| Q4149 | Excellagen, 0.1 cc | Investigational |
| Q4152 | DermaPure, per sq cm | Investigational |
| Q4158 | Kerecis Omega3, per sq cm | Investigational |
| Q4161 | bio-ConneKt wound matrix, per sq cm | Investigational |
| Q4164 | Helicoll, per sq cm | Investigational |
| Q4165 | Keramatrix or Kerasorb, per sq cm | Investigational |
| Q4166 | Cytal, per sq cm | Investigational |

| | | |
|-------|--|-----------------|
| Q4167 | Truskin, per sq cm | Investigational |
| Q4179 | FlowerDerm, per sq cm | Investigational |
| Q4182 | Transcyte, per sq cm | Investigational |
| Q4193 | Coll-e-Derm, per sq cm | Investigational |
| Q4196 | PuraPly AM, per sq cm | Investigational |
| Q4199 | Cygnus matrix, per sq cm | Investigational |
| Q4200 | SkinTE, per sq cm | Investigational |
| Q4202 | Keroxx (2.5 g/cc), 1 cc | Investigational |
| Q4203 | Derma-Gide, per sq cm | Investigational |
| Q4222 | ProgenaMatrix, per sq cm | Investigational |
| Q4251 | Vim, per sq cm | Investigational |
| Q4252 | Vendaje, per sq cm | Investigational |
| Q4253 | Zenith Amniotic Membrane, per sq cm | Investigational |
| Q4259 | Celera dual layer or celera dual membrane, per square centimeter | Investigational |
| Q4260 | Signature apatch, per square centimeter | Investigational |
| Q4261 | Tag, per square centimeter | Investigational |
| Q4262 | Dual layer impax membrane, per square centimeter | Investigational |
| Q4263 | Surgraft tl, per square centimeter | Investigational |
| Q4264 | Cocoon membrane, per square centimeter | Investigational |
| Q4265 | Neostim tl, per square centimeter | Investigational |
| Q4266 | Neostim membrane, per square centimeter | Investigational |
| Q4267 | Neostim dl, per square centimeter | Investigational |
| Q4268 | Surgraft ft, per square centimeter | Investigational |
| Q4269 | Surgraft xt, per square centimeter | Investigational |
| Q4270 | Complete sl, per square centimeter | Investigational |
| Q4271 | Complete ft, per square centimeter | Investigational |
| Q4272 | Esano a, per square centimeter | Investigational |
| Q4273 | Esano aaa, per square centimeter | Investigational |
| Q4274 | Esano ac, per square centimeter | Investigational |
| Q4275 | Esano aca, per square centimeter | Investigational |
| Q4276 | Orion, per square centimeter | Investigational |
| Q4277 | Woundplus membrane or e-graft, per square centimeter | Investigational |
| Q4278 | Epieffect, per square centimeter | Investigational |
| Q4280 | Xcell amnio matrix, per square centimeter | Investigational |
| Q4281 | Barrera sl or barrera dl, per square centimeter | Investigational |

| | | |
|--------------|---|-----------------|
| Q4282 | Cygnus dual, per square centimeter | Investigational |
| Q4283 | Biovance tri-layer or biovance 3l, per square centimeter | Investigational |
| Q4284 | Dermabind sl, per square centimeter | Investigational |
| Q4285 | Nudyn dl or nudyn dl mesh, per square centimeter | Investigational |
| Q4286 | Nudyn sl or nudyn slw, per square centimeter | Investigational |
| Q9982 | Flutemetamol F18, diagnostic, per study dose, up to 5 mCi | Investigational |
| Q9983 | Florbetaben F18, diagnostic, per study dose, up to 8.1 mCi | Investigational |
| S0596 | Phakic intraocular lens for correction of refractive error | Investigational |
| S1091 | Stent, noncoronary, temporary, with delivery system (Propel) | Investigational |
| S2117 | Arthroereisis, subtalar | Investigational |
| S2230 | Implantation of magnetic component of semi-implantable hearing device on ossicles in middle ear | Investigational |
| S2348 | Decompression procedure, percutaneous, of nucleus pulposus of intervertebral disc, using radiofrequency energy, single or multiple levels, lumbar | Investigational |
| S3722 | Dose optimization by area under the curve (AUC) analysis, for infusional 5-fluorouracil | Investigational |
| S8040 | Topographic brain mapping | Investigational |
| S8130 | Interferential current stimulator, 2 channel | Investigational |
| S8131 | Interferential current stimulator, 4 channel | Investigational |
| S8930 | Electrical stimulation of auricular acupuncture points; each 15 minutes of personal one-on-one contact with patient | Investigational |
| S9090 | Vertebral axial decompression, per session | Investigational |
| V2787 | Astigmatism correcting function of intraocular lens | Investigational |
| V2788 | Presbyopia correcting function of intraocular lens | Investigational |
| V2799 | Vision item or service, miscellaneous | Investigational |

| | | |
|--------------|--|---|
| 0001A | Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted; first dose | Investigational COVID-19 Effective:(04/18/2023) |
| 0002A | Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted; second dose | Investigational COVID-19 Effective:(04/18/2023) |
| 0003A | Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted; third dose | Investigational COVID-19 Effective:(04/18/2023) |
| 0003U | Oncology (ovarian) biochemical assays of five proteins (apolipoprotein A-1, CA 125 II, follicle stimulating hormone, human epididymis protein 4, transferrin), utilizing serum, algorithm reported as a likelihood score | Investigational |
| 0004A | Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted; booster dose | Investigational COVID-19 Effective:(04/18/2023) |
| 0004M | Scoliosis, DNA analysis of 53 single nucleotide polymorphisms (SNPs), using saliva, prognostic algorithm reported as a risk score | Investigational |

| | | |
|--------------|---|---|
| 0011A | Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage; first dose | Investigational COVID-19 Effective:(04/18/2023) |
| 0011M | Oncology, prostate cancer, mRNA expression assay of 12 genes (10 content and 2 housekeeping), RT-PCR test utilizing blood plasma and urine, algorithms to predict high-grade prostate cancer risk | Investigational |
| 0012A | Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage; second dose | Investigational COVID-19 Effective:(04/18/2023) |
| 0013A | Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5 mL dosage; third dose | Investigational COVID-19 Effective:(04/18/2023) |
| 0014M | Liver disease, analysis of 3 biomarkers (hyaluronic acid [HA], procollagen III amino terminal peptide [PIIINP], tissue inhibitor of metalloproteinase 1 [TIMP-1]), using immunoassays, utilizing serum, prognostic algorithm reported as a risk score and risk of liver fibrosis and liver-related clinical events within 5 years | Investigational |
| 0016M | Oncology (bladder), mRNA, microarray gene expression profiling of 209 genes, utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as molecular subtype (luminal, luminal infiltrated, basal, basal claudin-low, neuroendocrine-like) | Investigational |

| | | |
|--------------|---|---|
| 0018M | Transplantation medicine (allograft rejection, renal), measurement of donor and third-party-induced CD154+T-cytotoxic memory cells, utilizing whole peripheral blood, algorithm reported as a rejection risk score | Investigational |
| 0019M | Cardiovascular disease, plasma, analysis of protein biomarkers by aptamer-based microarray and algorithm reported as 4-year likelihood of coronary event in high-risk populations | Investigational |
| 0024U | Glycosylated acute phase proteins (GlycA), nuclear magnetic resonance spectroscopy, quantitative | Investigational |
| 0025U | Tenofovir, by liquid chromatography with tandem mass spectrometry (LC-MS/MS), urine, quantitative | Investigational |
| 0031A | Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x10 ¹⁰ viral particles/0.5mL dosage; single dose | Investigational COVID-19 Effective:(05/07/2023) |
| 0031U | CYP1A2 (cytochrome P450 family 1, subfamily A, member 2)(eg, drug metabolism) gene analysis, common variants (ie, *1F, *1K, *6, *7) | Investigational |
| 0034A | Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x10 ¹⁰ viral particles/0.5mL dosage; booster dose | Investigational COVID-19 Effective:(05/07/2023) |

| | | |
|--------------|---|-----------------|
| 0034U | TPMT (thiopurine S-methyltransferase), NUDT15 (nudix hydroxylase 15) (eg, thiopurine metabolism) gene analysis, common variants (ie, TPMT *2, *3A, *3B, *3C, *4, *5, *6, *8, *12; NUDT15 *3, *4, *5) | Investigational |
| 0035U | Neurology (prion disease), cerebrospinal fluid, detection of prion protein by quaking-induced conformational conversion, qualitative | Investigational |
| 0038U | Vitamin D, 25 hydroxy D2 and D3, by LC-MS/MS, serum microsample, quantitative | Investigational |
| 0039U | Deoxyribonucleic acid (DNA) antibody, double stranded, high avidity | Investigational |
| 0041U | Borrelia burgdorferi, antibody detection of 5 recombinant protein groups, by immunoblot, IgM | Investigational |
| 0042U | Borrelia burgdorferi, antibody detection of 12 recombinant protein groups, by immunoblot, IgG | Investigational |
| 0043U | Tick-borne relapsing fever Borrelia group, antibody detection to 4 recombinant protein groups, by immunoblot, IgM | Investigational |
| 0044U | Tick-borne relapsing fever Borrelia group, antibody detection to 4 recombinant protein groups, by immunoblot, IgG | Investigational |
| 0045U | Oncology (breast ductal carcinoma in situ), mRNA, gene expression profiling by real-time RT-PCR of 12 genes (7 content and 5 housekeeping), utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as recurrence score | Investigational |
| 0047U | Oncology (prostate), mRNA, gene expression profiling by real-time RT-PCR of 17 genes (12 content and 5 housekeeping), utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as a risk score | Investigational |

| | | |
|--------------|---|--|
| 0048U | Oncology (solid organ neoplasia), DNA, targeted sequencing of protein-coding exons of 468 cancer-associated genes, including interrogation for somatic mutations and microsatellite instability, matched with normal specimens, utilizing formalin-fixed paraffin-embedded tumor tissue, report of clinically significant mutation(s) | Investigational |
| 0050U | Targeted genomic sequence analysis panel, acute myelogenous leukemia, DNA analysis, 194 genes, interrogation for sequence variants, copy number variants or rearrangements | Investigational |
| 0051A | Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation; first dose | Investigational COVID-19 Effective:(04/18/2023) |
| 0051U | Prescription drug monitoring, evaluation of drugs present by liquid chromatography tandem mass spectrometry (LC-MS/MS), urine or blood, 31 drug panel, reported as quantitative results, detected or not detected, per date of service | Investigational |
| 0052A | Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation; second dose | Investigational COVID-19 Effective:(04/18/2023) |
| 0052U | Lipoprotein, blood, high resolution fractionation and quantitation of lipoproteins, including all five major lipoprotein classes and subclasses of HDL, LDL, and VLDL by vertical auto profile ultracentrifugation | Investigational |

| | | |
|--------------|--|---|
| 0053A | Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation; third dose | Investigational COVID-19 Effective:(04/18/2023) |
| 0054A | Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation; booster dose | Investigational COVID-19 Effective:(04/18/2023) |
| 0054U | Prescription drug monitoring, 14 or more classes of drugs and substances, definitive tandem mass spectrometry with chromatography, capillary blood, quantitative report with therapeutic and toxic ranges, including steady-state range for the prescribed dose when detected, per date of service | Investigational |
| 0055U | Cardiology (heart transplant), cell-free DNA, PCR assay of 96 DNA target sequences (94 single nucleotide polymorphism targets and two control targets), plasma | Investigational |
| 0058U | Oncology (Merkel cell carcinoma), detection of antibodies to the Merkel cell polyoma virus oncoprotein (small T antigen), serum, quantitative | Investigational |
| 0059U | Oncology (Merkel cell carcinoma), detection of antibodies to the Merkel cell polyoma virus capsid protein (VP1), serum, reported as positive or negative | Investigational |
| 0060U | Twin zygosity, genomic targeted sequence analysis of chromosome 2, using circulating cell-free fetal DNA in maternal blood | Investigational |

| | | |
|--------------|---|--|
| 0061U | Transcutaneous measurement of five biomarkers (tissue oxygenation [StO2], oxyhemoglobin [ctHbO2], deoxyhemoglobin [ctHbR], papillary and reticular dermal hemoglobin concentrations [ctHb1 and ctHb2]), using spatial frequency domain imaging (SFDI) and multi-spectral analysis | Investigational |
| 0062U | Autoimmune (systemic lupus erythematosus), IgG and IgM analysis of 80 biomarkers, utilizing serum, algorithm reported with a risk score | Investigational |
| 0064A | Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.25 mL dosage, booster dose | Investigational COVID-19 Effective:(04/18/2023) |
| 0067U | Oncology (breast), immunohistochemistry, protein expression profiling of 4 biomarkers (matrix metalloproteinase-1 [MMP-1], carcinoembryonic antigen-related cell adhesion molecule 6 [CEACAM6], hyaluronoglucosaminidase [HYAL1], highly expressed in cancer protein [HEC1]), formalin-fixed paraffin-embedded precancerous breast tissue, algorithm reported as carcinoma risk score | Investigational |
| 0069U | Oncology (colorectal), microRNA, RT-PCR expression profiling of miR-31-3p, formalin-fixed paraffin-embedded tissue, algorithm reported as an expression score | Investigational |

| | | |
|--------------|--|---|
| 0071A | Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; first dose | Investigational COVID-19 Effective:(04/18/2023) |
| 0071T | Focused ultrasound ablation of uterine leiomyomata, including MR guidance; total leiomyomata volume less than 200 cc of tissue | Investigational |
| 0072A | Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; second dose | Investigational COVID-19 Effective:(04/18/2023) |
| 0072T | Focused ultrasound ablation of uterine leiomyomata, including MR guidance; total leiomyomata volume greater or equal to 200 cc of tissue | Investigational |
| 0073A | Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; third dose | Investigational COVID-19 Effective:(04/18/2023) |
| 0074A | Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; booster dose | Investigational COVID-19 Effective:(04/18/2023) |

| | | |
|--------------|---|---|
| 0075T | Transcatheter placement of extracranial vertebral artery stent(s), including radiologic supervision and interpretation, open or percutaneous; initial vessel | Investigational |
| 0076T | Transcatheter placement of extracranial vertebral artery stent(s), including radiologic supervision and interpretation, open or percutaneous; each additional vessel (List separately in addition to code for primary procedure) | Investigational |
| 0078U | Pain management (opioid-use disorder) genotyping panel, 16 common variants (ie, ABCB1, COMT, DAT1, DBH, DOR, DRD1, DRD2, DRD4, GABA, GAL, HTR2A, HTTLPR, MTHFR, MUOR, OPRK1, OPRM1), buccal swab or other germline tissue sample, algorithm reported as positive or negative risk of opioid-use disorder | Investigational |
| 0080U | Oncology (lung), mass spectrometric analysis of galectin-3-binding protein and scavenger receptor cysteine-rich type 1 protein M130, with five clinical risk factors (age, smoking status, nodule diameter, nodule-spiculation status and nodule location), utilizing plasma, algorithm reported as a categorical probability of malignancy | Investigational |
| 0081A | Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; first dose | Investigational COVID-19 Effective:(04/18/2023) |

| | | |
|--------------|--|---|
| 0082A | Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; second dose | Investigational COVID-19 Effective:(04/18/2023) |
| 0082U | Drug test(s), definitive, 90 or more drugs or substances, definitive chromatography with mass spectrometry, and presumptive, any number of drug classes, by instrument chemistry analyzer (utilizing immunoassay), urine, report of presence or absence of each drug, drug metabolite or substance with description and severity of significant interactions per date of service | Investigational |
| 0083A | Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; third dose | Investigational COVID-19 Effective:(04/18/2023) |
| 0083U | Oncology, response to chemotherapy drugs using motility contrast tomography, fresh or frozen tissue, reported as likelihood of sensitivity or resistance to drugs or drug combinations | Investigational |
| 0084U | Red blood cell antigen typing, DNA, genotyping of 10 blood groups with phenotype prediction of 37 red blood cell antigens | Investigational |
| 0087U | Cardiology (heart transplant), mRNA gene expression profiling by microarray of 1283 genes, transplant biopsy tissue, allograft rejection and injury algorithm reported as a probability score | Investigational |

| | | |
|--------------|---|---|
| 0088U | Transplantation medicine (kidney allograft rejection), microarray gene expression profiling of 1494 genes, utilizing transplant biopsy tissue, algorithm reported as a probability score for rejection | Investigational |
| 0089U | Oncology (melanoma), gene expression profiling by RTqPCR, PRAME and LINC00518, superficial collection using adhesive patch(es) | Investigational |
| 0090U | Oncology (cutaneous melanoma), mRNA gene expression profiling by RT-PCR of 23 genes (14 content and 9 housekeeping), utilizing formalin-fixed paraffin-embedded (FFPE) tissue, algorithm reported as a categorical result (ie, benign, intermediate, malignant) | Investigational |
| 0091A | Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.5 mL dosage; first dose, when administered to individuals 6 through 11 years | Investigational COVID-19 Effective:(04/18/2023) |
| 0091U | Oncology (colorectal) screening, cell enumeration of circulating tumor cells, utilizing whole blood, algorithm, for the presence of adenoma or cancer, reported as a positive or negative result | Investigational |
| 0092A | Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.5 mL dosage; second dose, when administered to individuals 6 through 11 years | Investigational COVID-19 Effective:(04/18/2023) |

| | | |
|--------------|---|---|
| 0092U | Oncology (lung), three protein biomarkers, immunoassay using magnetic nanosensor technology, plasma, algorithm reported as risk score for likelihood of malignancy | Investigational |
| 0093A | Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.5 mL dosage; third dose, when administered to individuals 6 through 11 years | Investigational COVID-19 Effective:(04/18/2023) |
| 0094A | Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.5 mL dosage; booster dose, when administered to individuals 18 years and over | Investigational COVID-19 Effective:(04/18/2023) |
| 0095U | Eosinophilic esophagitis, Eotaxin-3 [CCL26 {C-C motif chemokine ligand 26}] and major basic protein [PRG2 {proteoglycan 2, pro eosinophil major basic protein}], enzyme-linked immunosorbent assays (ELISA), specimen obtained by esophageal string test device, algorithm reported as probability of active or inactive eosinophilic esophagitis | Investigational |
| 0100T | Placement of a subconjunctival retinal prosthesis receiver and pulse generator, and implantation of intra-ocular retinal electrode array, with vitrectomy | Investigational |
| 0101T | Extracorporeal shock wave involving musculoskeletal system, not otherwise specified | Investigational |

| | | |
|--------------|--|-----------------|
| 0101U | Hereditary colon cancer disorders (eg, Lynch syndrome, PTEN hamartoma syndrome, Cowden syndrome, familial adenomatosis polyposis), genomic sequence analysis panel utilizing a combination of NGS, Sanger, MLPA, and array CGH, with mRNA analytics to resolve variants of unknown significance when indicated (15 genes [sequencing and deletion/duplication], EPCAM and GREM1 [deletion/duplication only]) | Investigational |
| 0102T | Extracorporeal shock wave performed by a physician, requiring anesthesia other than local, and involving the lateral humeral epicondyle | Investigational |
| 0102U | Hereditary breast cancer-related disorders (eg, hereditary breast cancer, hereditary ovarian cancer, hereditary endometrial cancer), genomic sequence analysis panel utilizing a combination of NGS, Sanger, MLPA, and array CGH, with mRNA analytics to resolve variants of unknown significance when indicated (17 genes [sequencing and deletion/duplication]) | Investigational |
| 0103U | Hereditary ovarian cancer (eg, hereditary ovarian cancer, hereditary endometrial cancer), genomic sequence analysis panel utilizing a combination of NGS, Sanger, MLPA, and array CGH, with mRNA analytics to resolve variants of unknown significance when indicated (24 genes [sequencing and deletion/duplication], EPCAM [deletion/duplication only]) | Investigational |

| | | |
|--------------|---|-----------------|
| 0105U | Nephrology (chronic kidney disease), multiplex electrochemiluminescent immunoassay (ECLIA) of tumor necrosis factor receptor 1A, receptor superfamily 2 (TNFR1, TNFR2), and kidney injury molecule-1 (KIM-1) combined with longitudinal clinical data, including APOL1 genotype if available, and plasma (isolated fresh or frozen), algorithm reported as probability score for rapid kidney function decline (RKFD) | Investigational |
| 0106T | Quantitative sensory testing (QST), testing and interpretation per extremity; using touch pressure stimuli to assess large diameter sensation | Investigational |
| 0106U | Gastric emptying, serial collection of 7 timed breath specimens, non-radioisotope carbon-13 (13C) spirulina substrate, analysis of each specimen by gas isotope ratio mass spectrometry, reported as rate of 13CO2 excretion | Investigational |
| 0107T | Quantitative sensory testing (QST), testing and interpretation per extremity; using vibration stimuli to assess large diameter fiber sensation | Investigational |
| 0108T | Quantitative sensory testing (QST), testing and interpretation per extremity; using cooling stimuli to assess small nerve fiber sensation and hyperalgesia | Investigational |
| 0108U | Gastroenterology (Barrett's esophagus), whole slide-digital imaging, including morphometric analysis, computer-assisted quantitative immunolabeling of 9 protein biomarkers (p16, AMACR, p53, CD68, COX-2, CD45RO, HIF1a, HER-2, K20) and morphology, formalin-fixed paraffin-embedded tissue, algorithm reported as risk of progression to high-grade dysplasia or cancer | Investigational |

| | | |
|--------------|---|--|
| 0109T | Quantitative sensory testing (QST), testing and interpretation per extremity; using heat-pain stimuli to assess small nerve fiber sensation and hyperalgesia | Investigational |
| 0110T | Quantitative sensory testing (QST), testing and interpretation per extremity; using other stimuli to assess sensation | Investigational |
| 0110U | Prescription drug monitoring, one or more oral oncology drug(s) and substances, definitive tandem mass spectrometry with chromatography, serum or plasma from capillary blood or venous blood, quantitative report with steady-state range for the prescribed drug(s) when detected | Investigational |
| 0111A | Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage; first dose | Investigational COVID-19 Effective:(04/18/2023) |
| 0112A | Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 25 mcg/0.25 mL dosage; second dose | Investigational COVID-19 Effective:(04/18/2023) |
| 0113U | Oncology (prostate), measurement of PCA3 and TMPRSS2-ERG in urine and PSA in serum following prostatic massage, by RNA amplification and fluorescence-based detection, algorithm reported as risk score | Investigational |
| 0114U | Gastroenterology (Barrett's esophagus), VIM and CCNA1 methylation analysis, esophageal cells, algorithm reported as likelihood for Barrett's esophagus | Investigational |

| | | |
|--------------|---|-----------------|
| 0118U | Transplantation medicine, quantification of donor-derived cell-free DNA using whole genome next-generation sequencing, plasma, reported as percentage of donor-derived cell-free DNA in the total cell-free DNA | Investigational |
| 0119U | Cardiology, ceramides by liquid chromatography-tandem mass spectrometry, plasma, quantitative report with risk score for major cardiovascular events | Investigational |
| 0120U | Oncology (B-cell lymphoma classification), mRNA, gene expression profiling by fluorescent probe hybridization of 58 genes (45 content and 13 housekeeping genes), formalin-fixed paraffin-embedded tissue, algorithm reported as likelihood for primary mediastinal B-cell lymphoma (PMBCL) and diffuse large B-cell lymphoma (DLBCL) with cell of origin subtyping in the latter | Investigational |
| 0121U | Sickle cell disease, microfluidic flow adhesion (VCAM-1), whole blood | Investigational |
| 0122U | Sickle cell disease, microfluidic flow adhesion (P-Selectin), whole blood | Investigational |
| 0123U | Mechanical fragility, RBC, shear stress and spectral analysis profiling | Investigational |
| 0130U | Hereditary colon cancer disorders (eg, Lynch syndrome, PTEN hamartoma syndrome, Cowden syndrome, familial adenomatosis polyposis), targeted mRNA sequence analysis panel (APC, CDH1, CHEK2, MLH1, MSH2, MSH6, MUTYH, PMS2, PTEN, and TP53) (List separately in addition to code for primary procedure) | Investigational |

| | | |
|--------------|---|-----------------|
| 0131U | Hereditary breast cancer-related disorders (eg, hereditary breast cancer, hereditary ovarian cancer, hereditary endometrial cancer), targeted mRNA sequence analysis panel (13 genes) (List separately in addition to code for primary procedure) | Investigational |
| 0132U | Hereditary ovarian cancer-related disorders (eg, hereditary breast cancer, hereditary ovarian cancer, hereditary endometrial cancer), targeted mRNA sequence analysis panel (17 genes) (List separately in addition to code for primary procedure) | Investigational |
| 0133U | Hereditary prostate cancer-related disorders, targeted mRNA sequence analysis panel (11 genes) (List separately in addition to code for primary procedure) | Investigational |
| 0134U | Hereditary pan cancer (eg, hereditary breast and ovarian cancer, hereditary endometrial cancer, hereditary colorectal cancer), targeted mRNA sequence analysis panel (18 genes) (List separately in addition to code for primary procedure) | Investigational |
| 0135U | Hereditary gynecological cancer (eg, hereditary breast and ovarian cancer, hereditary endometrial cancer, hereditary colorectal cancer), targeted mRNA sequence analysis panel (12 genes) (List separately in addition to code for primary procedure) | Investigational |
| 0136U | ATM (ataxia telangiectasia mutated) (eg, ataxia telangiectasia) mRNA sequence analysis (List separately in addition to code for primary procedure) | Investigational |
| 0137U | PALB2 (partner and localizer of BRCA2) (eg, breast and pancreatic cancer) mRNA sequence analysis (List separately in addition to code for primary procedure) | Investigational |

| | | |
|--------------|---|-----------------|
| 0138U | BRCA1 (BRCA1, DNA repair associated), BRCA2 (BRCA2, DNA repair associated) (eg, hereditary breast and ovarian cancer) mRNA sequence analysis (List separately in addition to code for primary procedure) | Investigational |
| 0152U | Infectious disease (bacteria, fungi, parasites, and DNA viruses), microbial cell-free DNA, plasma, untargeted next-generation sequencing, report for significant positive pathogens | Investigational |
| 0153U | Oncology (breast), mRNA, gene expression profiling by next-generation sequencing of 101 genes, utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as a triple negative breast cancer clinical subtype(s) with information on immune cell involvement | Investigational |
| 0163T | Total disc arthroplasty (artificial disc), anterior approach, including discectomy to prepare interspace (other than for decompression), each additional interspace, lumbar (List separately in addition to code for primary procedure) | Investigational |
| 0163U | Oncology (colorectal) screening, biochemical enzyme-linked immunosorbent assay (ELISA) of 3 plasma or serum proteins (teratocarcinoma derived growth factor-1 [TDGF-1, Cripto-1], carcinoembryonic antigen [CEA], extracellular matrix protein [ECM]), with demographic data (age, gender, CRC-screening compliance) using a proprietary algorithm and reported as likelihood of CRC or advanced adenomas | Investigational |
| 0164T | Removal of total disc arthroplasty, (artificial disc), anterior approach, each additional interspace, lumbar (List separately in addition to code for primary procedure) | Investigational |

| | | |
|--------------|--|-----------------|
| 0164U | Gastroenterology (irritable bowel syndrome [IBS]), immunoassay for anti-CdtB and anti-vinculin antibodies, utilizing plasma, algorithm for elevated or not elevated qualitative results | Investigational |
| 0165T | Revision including replacement of total disc arthroplasty (artificial disc), anterior approach, each additional interspace, lumbar (List separately in addition to code for primary procedure) | Investigational |
| 0165U | Peanut allergen-specific quantitative assessment of multiple epitopes using enzyme-linked immunosorbent assay (ELISA), blood, individual epitope results and probability of peanut allergy | Investigational |
| 0166U | Liver disease, 10 biochemical assays (a2-macroglobulin, haptoglobin, apolipoprotein A1, bilirubin, GGT, ALT, AST, triglycerides, cholesterol, fasting glucose) and biometric and demographic data, utilizing serum, algorithm reported as scores for fibrosis, necroinflammatory activity, and steatosis with a summary interpretation | Investigational |
| 0169U | NUDT15 (nudix hydrolase 15) and TPMT (thiopurine S-methyltransferase) (eg, drug metabolism) gene analysis, common variants | Investigational |
| 0170U | Neurology (autism spectrum disorder [ASD]), RNA, next-generation sequencing, saliva, algorithmic analysis, and results reported as predictive probability of ASD diagnosis | Investigational |
| 0171U | Targeted genomic sequence analysis panel, acute myeloid leukemia, myelodysplastic syndrome, and myeloproliferative neoplasms, DNA analysis, 23 genes, interrogation for sequence variants, rearrangements and minimal residual disease, reported as presence/absence | Investigational |

| | | |
|--------------|--|-----------------|
| 0174U | Oncology (solid tumor), mass spectrometric 30 protein targets, formalin-fixed paraffin-embedded tissue, prognostic and predictive algorithm reported as likely, unlikely, or uncertain benefit of 39 chemotherapy and targeted therapeutic oncology agents | Investigational |
| 0176U | Cytolethal distending toxin B (CdtB) and vinculin IgG antibodies by immunoassay (ie, ELISA) | Investigational |
| 0178U | Peanut allergen-specific quantitative assessment of multiple epitopes using enzyme-linked immunosorbent assay (ELISA), blood, report of minimum eliciting exposure for a clinical reaction | Investigational |
| 0179U | Oncology (non-small cell lung cancer), cell-free DNA, targeted sequence analysis of 23 genes (single nucleotide variations, insertions and deletions, fusions without prior knowledge of partner/breakpoint, copy number variations), with report of significant mutation(s) | Investigational |
| 0180U | Red cell antigen (ABO blood group) genotyping (ABO), gene analysis Sanger/chain termination/conventional sequencing, ABO (ABO, alpha 1-3-N-acetylgalactosaminyltransferase and alpha 1-3-galactosyltransferase) gene, including subtyping, 7 exons | Investigational |
| 0181U | Red cell antigen (Colton blood group) genotyping (CO), gene analysis, AQP1 (aquaporin 1 [Colton blood group]) exon 1 | Investigational |
| 0182U | Red cell antigen (Cromer blood group) genotyping (CROM), gene analysis, CD55 (CD55 molecule [Cromer blood group]) exons 1-10 | Investigational |
| 0183U | Red cell antigen (Diego blood group) genotyping (DI), gene analysis, SLC4A1 (solute carrier family 4 member 1 [Diego blood group]) exon 19 | Investigational |

| | | |
|--------------|--|-----------------|
| 0184U | Red cell antigen (Dombrock blood group) genotyping (DO), gene analysis, ART4 (ADP-ribosyltransferase 4 [Dombrock blood group]) exon 2 | Investigational |
| 0185U | Red cell antigen (H blood group) genotyping (FUT1), gene analysis, FUT1 (fucosyltransferase 1 [H blood group]) exon 4 | Investigational |
| 0186U | Red cell antigen (H blood group) genotyping (FUT2), gene analysis, FUT2 (fucosyltransferase 2) exon 2 | Investigational |
| 0187U | Red cell antigen (Duffy blood group) genotyping (FY), gene analysis, ACKR1 (atypical chemokine receptor 1 [Duffy blood group]) exons 1-2 | Investigational |
| 0188U | Red cell antigen (Gerbich blood group) genotyping (GE), gene analysis, GYPC (glycophorin C [Gerbich blood group]) exons 1-4 | Investigational |
| 0189U | Red cell antigen (MNS blood group) genotyping (GYPA), gene analysis, GYPA (glycophorin A [MNS blood group]) introns 1, 5, exon 2 | Investigational |
| 0190U | Red cell antigen (MNS blood group) genotyping (GYPB), gene analysis, GYPB (glycophorin B [MNS blood group]) introns 1, 5, pseudoexon 3 | Investigational |
| 0191U | Red cell antigen (Indian blood group) genotyping (IN), gene analysis, CD44 (CD44 molecule [Indian blood group]) exons 2, 3, 6 | Investigational |
| 0192U | Red cell antigen (Kidd blood group) genotyping (JK), gene analysis, SLC14A1 (solute carrier family 14 member 1 [Kidd blood group]) gene promoter, exon 9 | Investigational |
| 0193U | Red cell antigen (JR blood group) genotyping (JR), gene analysis, ABCG2 (ATP binding cassette subfamily G member 2 [Junior blood group]) exons 2-26 | Investigational |
| 0194U | Red cell antigen (Kell blood group) genotyping (KEL), gene analysis, KEL (Kell metallo-endopeptidase [Kell blood group]) exon 8 | Investigational |
| 0195U | KLF1 (Kruppel-like factor 1), targeted sequencing (ie, exon 13) | Investigational |

| | | |
|--------------|---|-----------------|
| 0196U | Red cell antigen (Lutheran blood group) genotyping (LU), gene analysis, BCAM (basal cell adhesion molecule [Lutheran blood group]) exon 3 | Investigational |
| 0197U | Red cell antigen (Landsteiner-Wiener blood group) genotyping (LW), gene analysis, ICAM4 (intercellular adhesion molecule 4 [Landsteiner-Wiener blood group]) exon 1 | Investigational |
| 0198U | Red cell antigen (RH blood group) genotyping (RHD and RHCE), gene analysis Sanger/chain termination/conventional sequencing, RHD (Rh blood group D antigen) exons 1-10 and RHCE (Rh blood group CcEe antigens) exon 5 | Investigational |
| 0199U | Red cell antigen (Scianna blood group) genotyping (SC), gene analysis, ERMAP (erythroblast membrane associated protein [Scianna blood group]) exons 4, 12 | Investigational |
| 0200U | Red cell antigen (Kx blood group) genotyping (XK), gene analysis, XK (X-linked Kx blood group) exons 1-3 | Investigational |
| 0201U | Red cell antigen (Yt blood group) genotyping (YT), gene analysis, ACHE (acetylcholinesterase [Cartwright blood group]) exon 2 | Investigational |
| 0202T | Posterior vertebral joint(s) arthroplasty (eg, facet joint[s] replacement), including facetectomy, laminectomy, foraminotomy, and vertebral column fixation, injection of bone cement, when performed, including fluoroscopy, single level, lumbar spine | Investigational |
| 0203U | Autoimmune (inflammatory bowel disease), mRNA, gene expression profiling by quantitative RT-PCR, 17 genes (15 target and 2 reference genes), whole blood, reported as a continuous risk score and classification of inflammatory bowel disease aggressiveness | Investigational |

| | | |
|--------------|---|-----------------|
| 0204U | Oncology (thyroid), mRNA, gene expression analysis of 593 genes (including BRAF, RAS, RET, PAX8, and NTRK) for sequence variants and rearrangements, utilizing fine needle aspirate, reported as detected or not detected | Investigational |
| 0205U | Ophthalmology (age-related macular degeneration), analysis of 3 gene variants (2 CFH gene, 1 ARMS2 gene), using PCR and MALDI-TOF, buccal swab, reported as positive or negative for neovascular age-related macular-degeneration risk associated with zinc supplements | Investigational |
| 0206U | Neurology (Alzheimer disease); cell aggregation using morphometric imaging and protein kinase C-epsilon (PKCe) concentration in response to amylospheroid treatment by ELISA, cultured skin fibroblasts, each reported as positive or negative for Alzheimer disease | Investigational |
| 0207T | Evacuation of meibomian glands, automated, using heat and intermittent pressure, unilateral | Investigational |
| 0207U | Neurology (Alzheimer disease); quantitative imaging of phosphorylated ERK1 and ERK2 in response to bradykinin treatment by in situ immunofluorescence, using cultured skin fibroblasts, reported as a probability index for Alzheimer disease (List separately in addition to code for primary procedure) | Investigational |
| 0209U | Cytogenomic constitutional (genome-wide) analysis, interrogation of genomic regions for copy number, structural changes and areas of homozygosity for chromosomal abnormalities | Investigational |

| | | |
|--------------|---|-----------------|
| 0211U | Oncology (pan-tumor), DNA and RNA by next-generation sequencing, utilizing formalin-fixed paraffin-embedded tissue, interpretative report for single nucleotide variants, copy number alterations, tumor mutational burden, and microsatellite instability, with therapy association | Investigational |
| 0216U | Neurology (inherited ataxias), genomic DNA sequence analysis of 12 common genes including small sequence changes, deletions, duplications, short tandem repeat gene expansions, and variants in non-uniquely mappable regions, blood or saliva, identification and categorization of genetic variants | Investigational |
| 0217U | Neurology (inherited ataxias), genomic DNA sequence analysis of 51 genes including small sequence changes, deletions, duplications, short tandem repeat gene expansions, and variants in non-uniquely mappable regions, blood or saliva, identification and categorization of genetic variants | Investigational |
| 0218U | Neurology (muscular dystrophy), DMD gene sequence analysis, including small sequence changes, deletions, duplications, and variants in non-uniquely mappable regions, blood or saliva, identification and characterization of genetic variants | Investigational |
| 0219U | Infectious agent (human immunodeficiency virus), targeted viral next-generation sequence analysis (ie, protease [PR], reverse transcriptase [RT], integrase [INT]), algorithm reported as prediction of antiviral drug susceptibility | Investigational |
| 0220U | Red cell antigen (RH blood group) genotyping (RHD and RHCE), gene analysis, next-generation sequencing, RH proximal promoter, exons 1-10, portions of introns 2-3 | Investigational |

| | | |
|--------------|--|-----------------|
| 0227U | Drug assay, presumptive, 30 or more drugs or metabolites, urine, liquid chromatography with tandem mass spectrometry (LC-MS/MS) using multiple reaction monitoring (MRM), with drug or metabolite description, includes sample validation | Investigational |
| 0228U | Oncology (prostate), multianalyte molecular profile by photometric detection of macromolecules adsorbed on nanosponge array slides with machine learning, utilizing first morning voided urine, algorithm reported as likelihood of prostate cancer | Investigational |
| 0229U | BCAT1 (Branched chain amino acid transaminase 1) and IKZF1 (IKAROS family zinc finger 1) (eg, colorectal cancer) promoter methylation analysis | Investigational |
| 0232T | Injection(s), platelet rich plasma, any site, including image guidance, harvesting and preparation when performed | Investigational |
| 0242U | Targeted genomic sequence analysis panel, solid organ neoplasm, cell-free circulating DNA analysis of 55-74 genes, interrogation for sequence variants, gene copy number amplifications, and gene rearrangements | Investigational |
| 0243U | Obstetrics (preeclampsia), biochemical assay of placental-growth factor, time-resolved fluorescence immunoassay, maternal serum, predictive algorithm reported as a risk score for preeclampsia | Investigational |
| 0244U | Oncology (solid organ), DNA, comprehensive genomic profiling, 257 genes, interrogation for single-nucleotide variants, insertions/deletions, copy number alterations, gene rearrangements, tumor-mutational burden and microsatellite instability, utilizing formalin-fixed paraffin-embedded tumor tissue | Investigational |

| | | |
|--------------|--|-----------------|
| 0247U | Obstetrics (preterm birth), insulin-like growth factor-binding protein 4 (IBP4), sex hormone-binding globulin (SHBG), quantitative measurement by LC-MS/MS, utilizing maternal serum, combined with clinical data, reported as predictive-risk stratification for spontaneous preterm birth | Investigational |
| 0248U | Oncology (brain), spheroid cell culture in a 3D microenvironment, 12 drug panel, tumor-response prediction for each drug | Investigational |
| 0249U | Oncology (breast), semiquantitative analysis of 32 phosphoproteins and protein analytes, includes laser capture microdissection, with algorithmic analysis and interpretative report | Investigational |
| 0250U | Oncology (solid organ neoplasm), targeted genomic sequence DNA analysis of 505 genes, interrogation for somatic alterations (SNVs [single nucleotide variant], small insertions and deletions, one amplification, and four translocations), microsatellite instability and tumor-mutation burden | Investigational |
| 0251U | Hepcidin-25, enzyme-linked immunosorbent assay (ELISA), serum or plasma | Investigational |
| 0252U | Fetal aneuploidy short tandem-repeat comparative analysis, fetal DNA from products of conception, reported as normal (euploidy), monosomy, trisomy, or partial deletion/duplication, mosaicism, and segmental aneuploidy | Investigational |
| 0253T | Insertion of anterior segment aqueous drainage device, without extraocular reservoir, internal approach, into the suprachoroidal space | Investigational |

| | | |
|--------------|---|-----------------|
| 0253U | Reproductive medicine (endometrial receptivity analysis), RNA gene expression profile, 238 genes by next-generation sequencing, endometrial tissue, predictive algorithm reported as endometrial window of implantation (eg, pre-receptive, receptive, post-receptive) | Investigational |
| 0255U | Andrology (infertility), sperm-capacitation assessment of ganglioside GM1 distribution patterns, fluorescence microscopy, fresh or frozen specimen, reported as percentage of capacitated sperm and probability of generating a pregnancy score | Investigational |
| 0258U | Autoimmune (psoriasis), mRNA, next-generation sequencing, gene expression profiling of 50-100 genes, skin-surface collection using adhesive patch, algorithm reported as likelihood of response to psoriasis biologics | Investigational |
| 0259U | Nephrology (chronic kidney disease), nuclear magnetic resonance spectroscopy measurement of myo-inositol, valine, and creatinine, algorithmically combined with cystatin C (by immunoassay) and demographic data to determine estimated glomerular filtration rate (GFR), serum, quantitative | Investigational |
| 0260U | Rare diseases (constitutional/heritable disorders), identification of copy number variations, inversions, insertions, translocations, and other structural variants by optical genome mapping | Investigational |
| 0261U | Oncology (colorectal cancer), image analysis with artificial intelligence assessment of 4 histologic and immunohistochemical features (CD3 and CD8 within tumor-stroma border and tumor core), tissue, reported as immune response and recurrence-risk score | Investigational |

| | | |
|--------------|---|-----------------|
| 0262U | Oncology (solid tumor), gene expression profiling by real-time RT-PCR of 7 gene pathways (ER, AR, PI3K, MAPK, HH, TGFB, Notch), formalin-fixed paraffin-embedded (FFPE), algorithm reported as gene pathway activity score | Investigational |
| 0263T | Intramuscular autologous bone marrow cell therapy, with preparation of harvested cells, multiple injections, one leg, including ultrasound guidance, if performed; complete procedure including unilateral or bilateral bone marrow harvest | Investigational |
| 0263U | Neurology (autism spectrum disorder [ASD]), quantitative measurements of 16 central carbon metabolites (ie, a-ketoglutarate, alanine, lactate, phenylalanine, pyruvate, succinate, carnitine, citrate, fumarate, hypoxanthine, inosine, malate, S-sulfocysteine, taurine, urate, and xanthine), liquid chromatography tandem mass spectrometry (LC-MS/MS), plasma, algorithmic analysis with result reported as negative or positive (with metabolic subtypes of ASD) | Investigational |
| 0264T | Intramuscular autologous bone marrow cell therapy, with preparation of harvested cells, multiple injections, one leg, including ultrasound guidance, if performed; complete procedure excluding bone marrow harvest | Investigational |
| 0264U | Rare diseases (constitutional/heritable disorders), identification of copy number variations, inversions, insertions, translocations, and other structural variants by optical genome mapping | Investigational |

| | | |
|--------------|--|-----------------|
| 0265T | Intramuscular autologous bone marrow cell therapy, with preparation of harvested cells, multiple injections, one leg, including ultrasound guidance, if performed; unilateral or bilateral bone marrow harvest only for intramuscular autologous bone marrow cell therapy | Investigational |
| 0266T | Implantation or replacement of carotid sinus baroreflex activation device; total system (includes generator placement, unilateral or bilateral lead placement, intra-operative interrogation, programming, and repositioning, when performed) | Investigational |
| 0266U | Unexplained constitutional or other heritable disorders or syndromes, tissue-specific gene expression by whole-transcriptome and next-generation sequencing, blood, formalin-fixed paraffin-embedded (FFPE) tissue or fresh frozen tissue, reported as presence or absence of splicing or expression changes | Investigational |
| 0267T | Implantation or replacement of carotid sinus baroreflex activation device; lead only, unilateral (includes intra-operative interrogation, programming, and repositioning, when performed) | Investigational |
| 0267U | Rare constitutional and other heritable disorders, identification of copy number variations, inversions, insertions, translocations, and other structural variants by optical genome mapping and whole genome sequencing | Investigational |
| 0268T | Implantation or replacement of carotid sinus baroreflex activation device; pulse generator only (includes intra-operative interrogation, programming, and repositioning, when performed) | Investigational |

| | | |
|--------------|--|-----------------|
| 0269T | Revision or removal of carotid sinus baroreflex activation device; total system (includes generator placement, unilateral or bilateral lead placement, intra-operative interrogation, programming, and repositioning, when performed) | Investigational |
| 0270T | Revision or removal of carotid sinus baroreflex activation device; lead only, unilateral (includes intra-operative interrogation, programming, and repositioning, when performed) | Investigational |
| 0271T | Revision or removal of carotid sinus baroreflex activation device; pulse generator only (includes intra-operative interrogation, programming, and repositioning, when performed) | Investigational |
| 0272T | Interrogation device evaluation (in person), carotid sinus baroreflex activation system, including telemetric iterative communication with the implantable device to monitor device diagnostics and programmed therapy values, with interpretation and report (eg, battery status, lead impedance, pulse amplitude, pulse width, therapy frequency, pathway mode, burst mode, therapy start/stop times each day); | Investigational |
| 0273T | Interrogation device evaluation (in person), carotid sinus baroreflex activation system, including telemetric iterative communication with the implantable device to monitor device diagnostics and programmed therapy values, with interpretation and report (eg, battery status, lead impedance, pulse amplitude, pulse width, therapy frequency, pathway mode, burst mode, therapy start/stop times each day); with programming | Investigational |

| | | |
|--------------|--|-----------------|
| 0274T | Percutaneous laminotomy/laminectomy (interlaminar approach) for decompression of neural elements, (with or without ligamentous resection, discectomy, facetectomy and/or foraminotomy), any method, under indirect image guidance (eg, fluoroscopic, CT), single or multiple levels, unilateral or bilateral; cervical or thoracic | Investigational |
| 0275T | Percutaneous laminotomy/laminectomy (interlaminar approach) for decompression of neural elements, (with or without ligamentous resection, discectomy, facetectomy and/or foraminotomy), any method, under indirect image guidance (eg, fluoroscopic, CT), single or multiple levels, unilateral or bilateral; lumbar | Investigational |
| 0278T | Transcutaneous electrical modulation pain reprocessing (eg, scrambler therapy), each treatment session (includes placement of electrodes) | Investigational |
| 0279U | Hematology (von Willebrand disease [VWD]), von Willebrand factor (VWF) and collagen III binding by enzyme-linked immunosorbent assays (ELISA), plasma, report of collagen III binding | Investigational |
| 0280U | Hematology (von Willebrand disease [VWD]), von Willebrand factor (VWF) and collagen IV binding by enzyme-linked immunosorbent assays (ELISA), plasma, report of collagen IV binding | Investigational |
| 0281U | Hematology (von Willebrand disease [VWD]), von Willebrand propeptide, enzyme-linked immunosorbent assays (ELISA), plasma, diagnostic report of von Willebrand factor (VWF) propeptide antigen level | Investigational |

| | | |
|--------------|---|-----------------|
| 0282U | Red blood cell antigen typing, DNA, genotyping of 12 blood group system genes to predict 44 red blood cell antigen phenotypes | Investigational |
| 0283U | von Willebrand factor (VWF), type 2B, platelet-binding evaluation, radioimmunoassay, plasma | Investigational |
| 0284U | von Willebrand factor (VWF), type 2N, factor VIII and VWF binding evaluation, enzyme-linked immunosorbent assays (ELISA), plasma | Investigational |
| 0285U | Oncology, response to radiation, cell-free DNA, quantitative branched chain DNA amplification, plasma, reported as a radiation toxicity score | Investigational |
| 0288U | Oncology (lung), mRNA, quantitative PCR analysis of 11 genes (BAG1, BRCA1, CDC6, CDK2AP1, ERBB3, FUT3, IL11, LCK, RND3, SH3BGR, WNT3A) and 3 reference genes (ESD, TBP, YAP1), formalin-fixed paraffin-embedded (FFPE) tumor tissue, algorithmic interpretation reported as a recurrence risk score | Investigational |
| 0289U | Neurology (Alzheimer disease), mRNA, gene expression profiling by RNA sequencing of 24 genes, whole blood, algorithm reported as predictive risk score | Investigational |
| 0290U | Pain management, mRNA, gene expression profiling by RNA sequencing of 36 genes, whole blood, algorithm reported as predictive risk score | Investigational |
| 0291U | Psychiatry (mood disorders), mRNA, gene expression profiling by RNA sequencing of 144 genes, whole blood, algorithm reported as predictive risk score | Investigational |
| 0292U | Psychiatry (stress disorders), mRNA, gene expression profiling by RNA sequencing of 72 genes, whole blood, algorithm reported as predictive risk score | Investigational |

| | | |
|--------------|--|-----------------|
| 0293U | Psychiatry (suicidal ideation), mRNA, gene expression profiling by RNA sequencing of 54 genes, whole blood, algorithm reported as predictive risk score | Investigational |
| 0294U | Longevity and mortality risk, mRNA, gene expression profiling by RNA sequencing of 18 genes, whole blood, algorithm reported as predictive risk score | Investigational |
| 0295U | Oncology (breast ductal carcinoma in situ), protein expression profiling by immunohistochemistry of 7 proteins (COX2, FOXA1, HER2, Ki-67, p16, PR, SIAH2), with 4 clinicopathologic factors (size, age, margin status, palpability), utilizing formalin-fixed paraffin-embedded (FFPE) tissue, algorithm reported as a recurrence risk score | Investigational |
| 0296U | Oncology (oral and/or oropharyngeal cancer), gene expression profiling by RNA sequencing at least 20 molecular features (eg, human and/or microbial mRNA), saliva, algorithm reported as positive or negative for signature associated with malignancy | Investigational |
| 0297U | Oncology (pan tumor), whole genome sequencing of paired malignant and normal DNA specimens, fresh or formalin-fixed paraffin-embedded (FFPE) tissue, blood or bone marrow, comparative sequence analyses and variant identification | Investigational |
| 0298U | Oncology (pan tumor), whole transcriptome sequencing of paired malignant and normal RNA specimens, fresh or formalin-fixed paraffin-embedded (FFPE) tissue, blood or bone marrow, comparative sequence analyses and expression level and chimeric transcript identification | Investigational |

| | | |
|--------------|--|-----------------|
| 0299U | Oncology (pan tumor), whole genome optical genome mapping of paired malignant and normal DNA specimens, fresh frozen tissue, blood, or bone marrow, comparative structural variant identification | Investigational |
| 0300U | Oncology (pan tumor), whole genome sequencing and optical genome mapping of paired malignant and normal DNA specimens, fresh tissue, blood, or bone marrow, comparative sequence analyses and variant identification | Investigational |
| 0303U | Hematology, red blood cell (RBC) adhesion to endothelial/subendothelial adhesion molecules, functional assessment, whole blood, with algorithmic analysis and result reported as an RBC adhesion index; hypoxic | Investigational |
| 0304U | Hematology, red blood cell (RBC) adhesion to endothelial/subendothelial adhesion molecules, functional assessment, whole blood, with algorithmic analysis and result reported as an RBC adhesion index; normoxic | Investigational |
| 0305U | Hematology, red blood cell (RBC) functionality and deformity as a function of shear stress, whole blood, reported as a maximum elongation index | Investigational |
| 0306U | Oncology (minimal residual disease [MRD]), next-generation targeted sequencing analysis, cell-free DNA, initial (baseline) assessment to determine a patient specific panel for future comparisons to evaluate for MRD | Investigational |

| | | |
|--------------|--|-----------------|
| 0307U | Oncology (minimal residual disease [MRD]), next-generation targeted sequencing analysis of a patient-specific panel, cell-free DNA, subsequent assessment with comparison to previously analyzed patient specimens to evaluate for MRD | Investigational |
| 0308U | Cardiology (coronary artery disease [CAD]), analysis of 3 proteins (high sensitivity [hs] troponin, adiponectin, and kidney injury molecule-1 [KIM-1]), plasma, algorithm reported as a risk score for obstructive CAD | Investigational |
| 0309U | Cardiology (cardiovascular disease), analysis of 4 proteins (NT-proBNP, osteopontin, tissue inhibitor of metalloproteinase-1 [TIMP-1], and kidney injury molecule-1 [KIM-1]), plasma, algorithm reported as a risk score for major adverse cardiac event | Investigational |
| 0310U | Pediatrics (vasculitis, Kawasaki disease [KD]), analysis of 3 biomarkers (NT-proBNP, C-reactive protein, and T-uptake), plasma, algorithm reported as a risk score for KD | Investigational |
| 0311U | Infectious disease (bacterial), quantitative antimicrobial susceptibility reported as phenotypic minimum inhibitory concentration (MIC)-based antimicrobial susceptibility for each organisms identified | Investigational |

| | | |
|--------------|--|-----------------|
| 0312U | Autoimmune diseases (eg, systemic lupus erythematosus [SLE]), analysis of 8 IgG autoantibodies and 2 cell-bound complement activation products using enzyme-linked immunosorbent immunoassay (ELISA), flow cytometry and indirect immunofluorescence, serum, or plasma and whole blood, individual components reported along with an algorithmic SLE-likelihood assessment | Investigational |
| 0313U | Oncology (pancreas), DNA and mRNA next-generation sequencing analysis of 74 genes and analysis of CEA (CEACAM5) gene expression, pancreatic cyst fluid, algorithm reported as a categorical result (ie, negative, low probability of neoplasia or positive, high probability of neoplasia) | Investigational |
| 0314U | Oncology (cutaneous melanoma), mRNA gene expression profiling by RT-PCR of 35 genes (32 content and 3 housekeeping), utilizing formalin-fixed paraffin-embedded (FFPE) tissue, algorithm reported as a categorical result (ie, benign, intermediate, malignant) | Investigational |
| 0315U | Oncology (cutaneous squamous cell carcinoma), mRNA gene expression profiling by RT-PCR of 40 genes (34 content and 6 housekeeping), utilizing formalin-fixed paraffin-embedded (FFPE) tissue, algorithm reported as a categorical risk result (ie, Class 1, Class 2A, Class 2B) | Investigational |
| 0316U | <i>Borrelia burgdorferi</i> (Lyme disease), OspA protein evaluation, urine | Investigational |
| 0317U | Oncology (lung cancer), four-probe FISH (3q29, 3p22.1, 10q22.3, 10cen) assay, whole blood, predictive algorithm-generated evaluation reported as decreased or increased risk for lung cancer | Investigational |

| | | |
|--------------|---|-----------------|
| 0318U | Pediatrics (congenital epigenetic disorders), whole genome methylation analysis by microarray for 50 or more genes, blood | Investigational |
| 0319U | Nephrology (renal transplant), RNA expression by select transcriptome sequencing, using pretransplant peripheral blood, algorithm reported as a risk score for early acute rejection | Investigational |
| 0320U | Nephrology (renal transplant), RNA expression by select transcriptome sequencing, using posttransplant peripheral blood, algorithm reported as a risk score for acute cellular rejection | Investigational |
| 0321U | Infectious agent detection by nucleic acid (DNA or RNA), genitourinary pathogens, identification of 20 bacterial and fungal organisms and identification of 16 associated antibiotic-resistance genes, multiplex amplified probe technique | Investigational |
| 0322U | Neurology (autism spectrum disorder [ASD]), quantitative measurements of 14 acyl carnitines and microbiome-derived metabolites, liquid chromatography with tandem mass spectrometry (LC-MS/MS), plasma, results reported as negative or positive for risk of metabolic subtypes associated with ASD | Investigational |
| 0323U | Infectious agent detection by nucleic acid (DNA and RNA), central nervous system pathogen, metagenomic next-generation sequencing, Cerebrospinal fluid (CSF), identification of pathogenic bacteria, viruses, parasites or fungi | Investigational |

| | | |
|--------------|---|-----------------|
| 0328U | Drug assay, definitive, 120 or more drugs and metabolites, urine, quantitative liquid chromatography with tandem mass spectrometry (LC-MS/MS), includes specimen validity and algorithmic analysis describing drug or metabolite and presence or absence of risks for a significant patient adverse event, per date of service | Investigational |
| 0329U | Oncology (neoplasia), exome and transcriptome sequence analysis for sequence variants, gene copy number amplifications and deletions, gene rearrangements, microsatellite instability and tumor mutational burden utilizing DNA and RNA from tumor with and DNA from normal blood or saliva for subtraction, report of clinically significant mutation(s) with therapy associations | Investigational |
| 0330U | Infectious agent detection by nucleic acid (DNA or RNA), vaginal pathogen panel, identification of 27 organisms, amplified probe technique, vaginal swab | Investigational |
| 0330T | Tear film imaging, unilateral or bilateral, with interpretation and report | Investigational |
| 0331U | Oncology (hematolymphoid neoplasia), optical for copy number alterations and gene rearrangements utilizing DNA from blood or bone marrow, report of clinically significant alternations | Investigational |
| 0332T | Myocardial sympathetic innervation imaging, planar qualitative and quantitative assessment; with tomographic SPECT | Investigational |

| | | |
|--------------|--|-----------------|
| 0332U | Oncology (pan-tumor), genetic profiling of 8 DNA-regulatory (epigenetic) markers by quantitative polymerase chain reaction (qPCR), whole blood, reported as a high or low probability of responding to immune checkpoint-inhibitor therapy | Investigational |
| 0333U | Oncology (liver), surveillance for hepatocellular carcinoma (HCC) in highrisk patients, analysis of methylation patterns on circulating cell-free DNA (cfDNA) plus measurement of serum of AFP/AFP-L3 and oncoprotein des-gammarcarboxy-prothrombin (DCP), algorithm reported as normal or abnormal result | Investigational |
| 0334U | Oncology (solid organ), targeted genomic sequence analysis, formalin-fixed paraffinembedded (FFPE) tumor tissue, DNA analysis, 84 or more genes, interrogation for sequence variants, gene copy number amplifications, gene rearrangements, microsatellite instability and tumor mutational burden | Investigational |
| 0335T | Insertion of sinus tarsi implant | Investigational |
| 0335U | rare diseases (constitutional/heritable disorders), whole genome sequence analysis, including small sequence changes, copy number variants, deletions, duplications, mobile element insertions, uniparental disomy (UPD), inversions, aneuploidy, mitochondrial genome sequence analysis with heteroplasmy and large deletions, short tandem repeat (STR) gene expansions, fetal sample, identification and categorization of genetic variants | Investigational |

| | | |
|--------------|--|-----------------|
| 0336U | Rare diseases (constitutional/heritable disorders), whole genome sequence analysis, including small sequence changes, copy number variants, deletions, duplications, mobile element insertions, uniparental disomy (UPD), inversions, aneuploidy, mitochondrial genome sequence analysis with heteroplasmy and large deletions, short tandem repeat (STR) gene expansions, blood or saliva, identification and categorization of genetic variants, each comparator genome (eg, parent) | Investigational |
| 0337U | Oncology (plasma cell disorders and myeloma), circulating plasma cell immunologic selection, identification, morphological characterization, and enumeration of plasma cells based on differential CD138, CD38, CD19, and CD45 protein biomarker expression, peripheral blood | Investigational |
| 0338T | Transcatheter renal sympathetic denervation, percutaneous approach including arterial puncture, selective catheter placement(s) renal artery(ies), fluoroscopy, contrast injection(s), intraprocedural roadmapping and radiological supervision and interpretation, including pressure gradient measurements, flush aortogram and diagnostic renal angiography when performed; unilateral | Investigational |
| 0338U | Oncology (solid tumor), circulating tumor cell selection, identification, morphological characterization, detection and enumeration based on differential EpCAM, cytokeratins 8, 18, and 19, and CD45 protein biomarkers, and quantification of HER2 protein biomarker-expressing cells, peripheral blood | Investigational |

| | | |
|--------------|--|-----------------|
| 0339T | Transcatheter renal sympathetic denervation, percutaneous approach including arterial puncture, selective catheter placement(s) renal artery(ies), fluoroscopy, contrast injection(s), intraprocedural roadmapping and radiological supervision and interpretation, including pressure gradient measurements, flush aortogram and diagnostic renal angiography when performed; bilateral | Investigational |
| 0339U | Oncology (prostate), mRNA expression profiling of HOXC6 and DLX1, reverse transcription polymerase chain reaction (RT-PCR), first-void urine following digital rectal examination, algorithm reported as probability of high-grade cancer | Investigational |
| 0340U | Oncology (pan-cancer), analysis of minimal residual disease (MRD) from plasma, with assays personalized to each patient based on prior next-generation sequencing of the patient's tumor and germline DNA, reported as absence or presence of MRD, with disease-burden correlation, if appropriate | Investigational |
| 0341U | Fetal aneuploidy DNA sequencing comparative analysis, fetal DNA from products of conception, reported as normal (euploidy), monosomy, trisomy, or partial deletion/duplication, mosaicism, and segmental aneuploid | Investigational |
| 0342U | Oncology (pancreatic cancer), multiplex immunoassay of C5, C4, cystatin C, factor B, osteoprotegerin (OPG), gelsolin, IGFBP3, CA125 and multiplex electrochemiluminescent immunoassay (ECLIA) for CA19-9, serum, diagnostic algorithm reported qualitatively as positive, negative, or borderline | Investigational |

| | | |
|--------------|--|-----------------|
| 0343U | Oncology (prostate), exosome-based analysis of 442 small noncoding RNAs (sncRNAs) by quantitative reverse transcription polymerase chain reaction (RT-qPCR), urine, reported as molecular evidence of no-, low-, intermediate- or high-risk of prostate cancer | Investigational |
| 0344U | Hepatology (nonalcoholic fatty liver disease [NAFLD]), semiquantitative evaluation of 28 lipid markers by liquid chromatography with tandem mass spectrometry (LC-MS/MS), serum, reported as at-risk for nonalcoholic steatohepatitis (NASH) or not NASH | Investigational |
| 0345U | Psychiatry (eg, depression, anxiety, attention deficit hyperactivity disorder [ADHD]), genomic analysis panel, variant analysis of 15 genes, including deletion/duplication analysis of CYP2D6 | Investigational |
| 0346U | Beta amyloid, Aβ40 and Aβ42 by liquid chromatography with tandem mass spectrometry (LC-MS/MS), ratio, plasma | Investigational |
| 0347U | Drug metabolism or processing (multiple conditions), whole blood or buccal specimen, DNA analysis, 16 gene report, with variant analysis and reported phenotypes | Investigational |
| 0348U | Drug metabolism or processing (multiple conditions), whole blood or buccal specimen, DNA analysis, 25 gene report, with variant analysis and reported phenotypes | Investigational |
| 0349U | Drug metabolism or processing (multiple conditions), whole blood or buccal specimen, DNA analysis, 27 gene report, with variant analysis, including reported phenotypes and impacted gene-drug interactions | Investigational |

| | | |
|--------------|--|-----------------|
| 0350U | Drug metabolism or processing (multiple conditions), whole blood or buccal specimen, DNA analysis, 27 gene report, with variant analysis and reported phenotypes | Investigational |
| 0351U | Infectious disease (bacterial or viral), biochemical assays, tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), interferon gamma-induced protein-10 (IP10), and C-reactive protein, serum, algorithm reported as likelihood of bacterial infection | Investigational |
| 0352U | Infectious disease (bacterial vaginosis and vaginitis), multiplex amplified probe technique, for detection of bacterial vaginosis-associated bacteria (BVAB-2, Atopobium vaginae, and Megasphaera type 1), algorithm reported as detected or not detected and separate detection of Candida species (C. albicans, C. tropicalis, C. parapsilosis, C. dubliniensis), Candida glabrata/Candida krusei, and trichomonas vaginalis, vaginal-fluid specimen, each result reported as detected or not detected | Investigational |
| 0355U | APOL1 (apolipoprotein L1) (eg, chronic kidney disease), risk variants (G1, G2) | Investigational |
| 0356U | Oncology (oropharyngeal), evaluation of 17 DNA biomarkers using droplet digital PCR (ddPCR), cell-free DNA, algorithm reported as a prognostic risk score for cancer recurrence | Investigational |
| 0358U | Neurology (mild cognitive impairment), analysis of β -amyloid 1-42 and 1-40, chemiluminescence enzyme immunoassay, cerebral spinal fluid, reported as positive, likely positive, or negative | Investigational |

| | | |
|--------------|---|-----------------|
| 0359U | Oncology (prostate cancer), analysis of all prostate-specific antigen (PSA) structural isoforms by phase separation and immunoassay, plasma, algorithm reports risk of cancer | Investigational |
| 0360U | Oncology (lung), enzyme-linked immunosorbent assay (ELISA) of 7 autoantibodies (p53, NY-ESO-1, CAGE, GBU4-5, SOX2, MAGE A4, and HuD), plasma, algorithm reported as a categorical result for risk of malignancy | Investigational |
| 0361U | Neurofilament light chain, digital immunoassay, plasma, quantitative | Investigational |
| 0362U | Oncology (papillary thyroid cancer), gene-expression profiling via targeted hybrid capture-enrichment RNA sequencing of 82 content genes fine needle aspiration or formalin-fixed paraffin embedded (FFPE) tissue, algorithm reported as one of three molecular subtypes | Investigational |
| 0363U | Oncology (urothelial), mRNA, geneexpression profiling by real-time quantitative PCR of 5 genes (MDK, HOXA13, CDC2 [CDK1], IGFBP5, and CXCR2), utilizing urine, algorithm incorporates age, sex, smoking history, and macrohematuria frequency, reported as a risk score for having urothelial carcinoma | Investigational |
| 0364U | Oncology (hematolymphoid neoplasm), genomic sequence analysis using multiplex (PCR) and next-generation sequencing with algorithm, quantification of dominant clonal sequence(s), reported as presence or absence of minimal residual disease (MRD) with quantitation of disease burden, when appropriate | Investigational |

| | | |
|--------------|--|-----------------|
| 0365U | Oncology (bladder), analysis of 10 protein biomarkers (A1AT, ANG, APOE, CA9, IL8, MMP9, MMP10, PAI1, SDC1 and VEGFA) by immunoassays, urine, algorithm reported as a probability of bladder cancer | Investigational |
| 0366U | Oncology (bladder), analysis of 10 protein biomarkers (A1AT, ANG, APOE, CA9, IL8, MMP9, MMP10, PAI1, SDC1 and VEGFA) by immunoassays, urine, algorithm reported as a probability of recurrent bladder cancer | Investigational |
| 0367U | Oncology (bladder), analysis of 10 protein biomarkers (A1AT, ANG, APOE, CA9, IL8, MMP9, MMP10, PAI1, SDC1 and VEGFA) by immunoassays, urine, diagnostic algorithm reported as a risk score for probability of rapid recurrence of recurrent or persistent cancer following transurethral resection | Investigational |
| 0369U | Infectious agent detection by nucleic acid (DNA and RNA), gastrointestinal pathogens, 31 bacterial, viral, and parasitic organisms and identification of 21 associated antibiotic-resistance genes, multiplex amplified probe technique | Investigational |
| 0370U | Infectious agent detection by nucleic acid (DNA and RNA), surgical wound pathogens, 34 microorganisms and identification of 21 associated antibiotic-resistance genes, multiplex amplified probe technique, wound swab | Investigational |
| 0371U | Infectious agent detection by nucleic acid (DNA or RNA), genitourinary pathogen, semiquantitative identification, DNA from 16 bacterial organisms and 1 fungal organism, multiplex amplified probe technique via quantitative polymerase chain reaction (qPCR), urine | Investigational |

| | | |
|--------------|---|-----------------|
| 0372U | Infectious disease (genitourinary pathogens), antibiotic-resistance gene detection, multiplex amplified probe technique, urine, reported as an antimicrobial stewardship risk score | Investigational |
| 0374U | Infectious agent detection by nucleic acid (DNA or RNA), genitourinary pathogens, identification of 21 bacterial and fungal organisms and identification of 21 associated antibiotic-resistance genes, multiplex amplified probe technique, urine | Investigational |
| 0375U | Oncology (ovarian), biochemical assays of 7 proteins (follicle stimulating hormone, human epididymis protein 4, apolipoprotein A-1, transferrin, beta-2 macroglobulin, prealbumin [ie, transthyretin], and cancer antigen 125), algorithm reported as ovarian cancer risk score | Investigational |
| 0376U | Oncology (ovarian), biochemical assays of 7 proteins (follicle stimulating hormone, human epididymis protein 4, apolipoprotein A-1, transferrin, beta-2 macroglobulin, prealbumin [ie, transthyretin], and cancer antigen 125), algorithm reported as ovarian cancer risk score | Investigational |
| 0377U | Cardiovascular disease, quantification of advanced serum or plasma lipoprotein profile, by nuclear magnetic resonance (NMR) spectrometry with report of a lipoprotein profile (including 23 variables) | Investigational |
| 0378U | RFC1 (replication factor C subunit 1), repeat expansion variant analysis by traditional and repeat-primed PCR, blood, saliva, or buccal swab | Investigational |

| | | |
|--------------|---|-----------------|
| 0379U | Targeted genomic sequence analysis panel, solid organ neoplasm, DNA (523 genes) and RNA (55 genes) by next-generation sequencing, interrogation for sequence variants, gene copy number amplifications, gene rearrangements, microsatellite instability, and tumor mutational burden | Investigational |
| 0380U | Drug metabolism (adverse drug reactions and drug response), targeted sequence analysis, 20 gene variants and CYP2D6 deletion or duplication analysis with reported genotype and phenotype | Investigational |
| 0384U | Nephrology (chronic kidney disease), carboxymethyllysine, methylglyoxal hydroimidazolone, and carboxyethyl lysine by liquid chromatography with tandem mass spectrometry (LCMS/MS) and HbA1c and estimated glomerular filtration rate (GFR), with risk score reported for predictive progression to high-stage kidney disease | Investigational |
| 0385U | Nephrology (chronic kidney disease), apolipoprotein A4 (ApoA4), CD5 antigen-like (CD5L), and insulin-like growth factor binding protein 3 (IGFBP3) by enzyme-linked immunoassay (ELISA), plasma, algorithm combining results with HDL, estimated glomerular filtration rate (GFR) and clinical data reported as a risk score for developing diabetic kidney disease | Investigational |
| 0387U | Oncology (melanoma), autophagy and beclin 1 regulator 1 (AMBRA1) and loricrin (AMLo) by immunohistochemistry, formalin-fixed paraffin-embedded (FFPE) tissue, report for risk of progression | Investigational |

| | | |
|--------------|---|-----------------|
| 0389U | Pediatric febrile illness (Kawasaki disease [KD]), interferon alpha-inducible protein 27 (IFI27) and mast cell-expressed membrane protein 1 (MCEMP1), RNA, using quantitative reverse transcription polymerase chain reaction (RT-qPCR), blood, reported as a risk score for KD | Investigational |
| 0390U | Obstetrics (preeclampsia), kinase insert domain receptor (KDR), Endoglin (ENG), and retinol-binding protein 4 (RBP4), by immunoassay, serum, algorithm reported as a risk score | Investigational |
| 0391U | "Oncology (solid tumor), DNA and RNA by next-generation sequencing, utilizing formalin-fixed paraffin-embedded (FFPE) tissue, 437 genes, interpretive report for single nucleotide variants, splice site variants, insertions/deletions, copy number alterations, gene fusions, tumor mutational burden, and microsatellite instability, with algorithm quantifying immunotherapy response score" | Investigational |
| 0392U | "Drug metabolism (depression, anxiety, attention deficit hyperactivity disorder [ADHD]), gene-drug interactions, variant analysis of 16 genes, including deletion/duplication analysis of CYP2D6, reported as impact of gene-drug interaction for each drug" | Investigational |

| | | |
|--------------|---|-----------------|
| 0393U | SYNTap® Biomarker Test by Amprion Clinical Laboratory. The lab, this chemistry test aids in the diagnosis of synucleinopathies (e.g., Parkinson's disease, Lewy body dementia, multiple system atrophy (MSA), Lewy body variant of Alzheimer's disease) and differential diagnosis of other movement and cognitive disorders. A CSF specimen is subjected to qualitative seed amplification assay assessment for detection of misfolded aggregates of α -synuclein protein | Investigational |
| 0394U | PFAS Testing & PFASure™, by National Medical Services (NMS Labs). Per the lab, this chemistry quantitative toxicology test, monitors for Perfluoroalkyl Substances, (eg. perfluorooctanoic acid, perfluorooctane sulfonic acid). Plasma or serum is analyzed by HPLC/Tandem Mass Spectrometry (LC-MS/MS) for 16 PFAS compounds and reported with a calculated NASEM Summation value (National Academies of Science, Engineering and Medicine guidance value). The US Department of Defense, Lab Corp (and other large national clinical laboratories) and individual State-Level agencies will order this testing in Serum/Plasma matrix to monitor for exposure to PFAS. NMS Labs anticipates that testing will begin in Q1 2023. Testing will be high volume. | Investigational |
| 0395U | "Oncology (lung), multi-omics (microbial DNA by shotgun nextgeneration sequencing and carcinoembryonic antigen and osteopontin by immunoassay), plasma, algorithm reported as malignancy risk for lung nodules in early-stage disease" | Investigational |

| | | |
|--------------|---|-----------------|
| 0397T | Endoscopic retrograde cholangiopancreatography (ERCP), with optical endomicroscopy (List separately in addition to code for primary procedure) | Investigational |
| 0398U | "Gastroenterology (Barrett esophagus), P16, RUNX3, HPP1, and FBN1 DNA methylation analysis using PCR, formalin-fixed paraffin-embedded (FFPE) tissue, algorithm reported as risk score for progression to high-grade dysplasia or cancer" | Investigational |
| 0399U | Neurology (cerebral folate deficiency), serum, detection of anti-human folate receptor IgGbinding antibody and blocking autoantibodies by enzyme-linked immunoassay (ELISA), qualitative, and blocking autoantibodies, using a functional blocking assay for IgG or IgM, quantitative, reported as positive or not detected | Investigational |
| 0400U | Obstetrics (expanded carrier screening), 145 genes by nextgeneration sequencing, fragment analysis and multiplex ligationdependent probe amplification, DNA, reported as carrier positive or negative | Investigational |
| 0401U | Cardiology (coronary heart disease [-CHD]), 9 genes (12 variants), targeted variant genotyping, blood, saliva, or buccal swab, algorithm reported as a genetic risk score for a coronary event | Investigational |
| 0403U | Oncology (prostate), mRNA, gene expression profiling of 18 genes, first-catch post-digital rectal examination urine (or processed first-catch urine), algorithm reported as percentage of likelihood of detecting clinically significant prostate cancer | Investigational |
| 0404T | Transcervical uterine fibroid(s) ablation with ultrasound guidance, radiofrequency | Investigational |

| | | |
|--------------|---|-----------------|
| 0404U | Oncology (breast), semiquantitative measurement of thymidine kinase activity by immunoassay, serum, results reported as risk of disease progression | Investigational |
| 0405U | Oncology (pancreatic), 59 methylation haplotype block markers, next-generation sequencing, plasma, reported as cancer signal detected or not detected | Investigational |
| 0406U | Oncology (lung), flow cytometry, sputum, 5 markers (meso-tetra [4-carboxyphenyl] porphyrin [TCPP], CD206, CD66b, CD3, CD19), algorithm reported as likelihood of lung cancer | Investigational |
| 0407U | Nephrology (diabetic chronic kidney disease [CKD]), multiplex electrochemiluminescent immunoassay (ECLIA) of soluble tumor necrosis factor receptor 1 (sTNFR1), soluble tumor necrosis receptor 2 (sTNFR2), and kidney injury molecule 1 (KIM-1) combined with clinical data, plasma, algorithm reported as risk for progressive decline in kidney function | Investigational |
| 0408U | Infectious agent antigen detection by bulk acoustic wave biosensor immunoassay, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) | Investigational |
| 0410U | Oncology (pancreatic), DNA, whole genome sequencing with 5-hydroxymethylcytosine enrichment, whole blood or plasma, algorithm reported as cancer detected or not detected | Investigational |
| 0411U | Psychiatry (eg, depression, anxiety, attention deficit hyperactivity disorder [ADHD]), genomic analysis panel, variant analysis of 15 genes, including deletion/duplication analysis of CYP2D6 (For additional PLA code with identical clinical descriptor, see 0345U. See Appendix O to determine appropriate code assignment) | Investigational |

| | | |
|--------------|--|-----------------|
| 0412U | Beta amyloid, AB42/40 ratio, immunoprecipitation with quantitation by liquid chromatography with tandem mass spectrometry (LC-MS/MS) and qualitative ApoE isoform-specific proteotyping, plasma combined with age, algorithm reported as presence or absence of brain amyloid pathology | Investigational |
| 0413U | Oncology (hematolymphoid neoplasm), optical genome mapping for copy number alterations, aneuploidy, and balanced/complex structural rearrangements, DNA from blood or bone marrow, report of clinically significant alterations | Investigational |
| 0414U | Oncology (lung), augmentative algorithmic analysis of digitized whole slide imaging for 8 genes (ALK, BRAF, EGFR, ERBB2, MET, NTRK1-3, RET, ROS1), and KRAS G12C and PD-L1, if performed, formalin-fixed paraffinembedded (FFPE) tissue, reported as positive or negative for each biomarker | Investigational |
| 0415U | Cardiovascular disease (acute coronary syndrome [ACS]), IL-16, FAS, FASLigand, HGF, CTACK, EOTAXIN, and MCP-3 by immunoassay combined with age, sex, family history, and personal history of diabetes, blood, algorithm reported as a 5-year (deleted risk) score for ACS | Investigational |
| 0416U | Infectious agent detection by nucleic acid (DNA), genitourinary pathogens, identification of 20 bacterial and fungal organisms, including identification of 20 associated antibiotic-resistance genes, if performed, multiplex amplified probe technique, urine | Investigational |

| | | |
|--------------|--|-----------------|
| 0417U | Rare diseases (constitutional/heritable disorders), whole mitochondrial genome sequence with heteroplasmy detection and deletion analysis, nuclearencoded mitochondrial gene analysis of 335 nuclear genes, including sequence changes, deletions, insertions, and copy number variants analysis, blood or saliva, identification and categorization of mitochondrial disorder-associated genetic variants | Investigational |
| 0418U | Oncology (breast), augmentative algorithmic analysis of digitized whole slide imaging of 8 histologic and immunohistochemical features, reported as a recurrence score | Investigational |
| 0419U | Neuropsychiatry (eg, depression, anxiety), genomic sequence analysis panel, variant analysis of 13 genes, saliva or buccal swab, report of each gene phenotype | Investigational |
| 0424T | Insertion or replacement of neurostimulator system for treatment of central sleep apnea; complete system (transvenous placement of right or left stimulation lead, sensing lead, implantable pulse generator) | Investigational |
| 0425T | Insertion or replacement of neurostimulator system for treatment of central sleep apnea; sensing lead only | Investigational |
| 0426T | Insertion or replacement of neurostimulator system for treatment of central sleep apnea; stimulation lead only | Investigational |
| 0427T | Insertion or replacement of neurostimulator system for treatment of central sleep apnea; pulse generator only | Investigational |
| 0428T | Removal of neurostimulator system for treatment of central sleep apnea; pulse generator only | Investigational |
| 0429T | Removal of neurostimulator system for treatment of central sleep apnea; sensing lead only | Investigational |

| | | |
|--------------|---|-----------------|
| 0430T | Removal of neurostimulator system for treatment of central sleep apnea; stimulation lead only | Investigational |
| 0431T | Removal and replacement of neurostimulator system for treatment of central sleep apnea, pulse generator only | Investigational |
| 0432T | Repositioning of neurostimulator system for treatment of central sleep apnea; stimulation lead only | Investigational |
| 0433T | Repositioning of neurostimulator system for treatment of central sleep apnea; sensing lead only | Investigational |
| 0434T | Interrogation device evaluation implanted neurostimulator pulse generator system for central sleep apnea | Investigational |
| 0435T | Programming device evaluation of implanted neurostimulator pulse generator system for central sleep apnea; single session | Investigational |
| 0436T | Programming device evaluation of implanted neurostimulator pulse generator system for central sleep apnea; during sleep study | Investigational |
| 0441T | Ablation, percutaneous, cryoablation, includes imaging guidance; lower extremity distal/peripheral nerve | Investigational |
| 0506T | Macular pigment optical density measurement by heterochromatic flicker photometry, unilateral or bilateral, with interpretation and report | Investigational |
| 0507T | Near-infrared dual imaging (ie, simultaneous reflective and trans-illuminated light) of meibomian glands, unilateral or bilateral, with interpretation and report | Investigational |
| 0508T | Pulse-echo ultrasound bone density measurement resulting in indicator of axial bone mineral density, tibia | Investigational |
| 0509T | Electroretinography (ERG) with interpretation and report, pattern (PERG) | Investigational |
| 0510T | Removal of sinus tarsi implant | Investigational |
| 0511T | Removal and reinsertion of sinus tarsi implant | Investigational |

| | | |
|--------------|--|-----------------|
| 0512T | Extracorporeal shock wave for integumentary wound healing, including topical application and dressing care; initial wound | Investigational |
| 0513T | Extracorporeal shock wave for integumentary wound healing, including topical application and dressing care; each additional wound (List separately in addition to code for primary procedure) | Investigational |
| 0515T | Insertion of wireless cardiac stimulator for left ventricular pacing, including device interrogation and programming, and imaging supervision and interpretation, when performed; complete system (includes electrode and generator [transmitter and battery]) | Investigational |
| 0516T | Insertion of wireless cardiac stimulator for left ventricular pacing, including device interrogation and programming, and imaging supervision and interpretation, when performed; electrode only | Investigational |
| 0517T | Insertion of wireless cardiac stimulator for left ventricular pacing, including device interrogation and programming, and imaging supervision and interpretation, when performed; pulse generator component(s) (battery and/or transmitter) only | Investigational |
| 0518T | Removal of only pulse generator component(s) (battery and/or transmitter) of wireless cardiac stimulator for left ventricular pacing | Investigational |
| 0519T | Removal and replacement of wireless cardiac stimulator for left ventricular pacing; pulse generator component(s) (battery and/or transmitter) | Investigational |
| 0520T | Removal and replacement of wireless cardiac stimulator for left ventricular pacing; pulse generator component(s) (battery and/or transmitter), including placement of a new electrode | Investigational |

| | | |
|--------------|--|-----------------|
| 0521T | Interrogation device evaluation (in person) with analysis, review and report, includes connection, recording, and disconnection per patient encounter, wireless cardiac stimulator for left ventricular pacing | Investigational |
| 0522T | Programming device evaluation (in person) with iterative adjustment of the implantable device to test the function of the device and select optimal permanent programmed values with analysis, including review and report, wireless cardiac stimulator for left ventricular pacing | Investigational |
| 0523T | Intraprocedural coronary fractional flow reserve (FFR) with 3D functional mapping of color-coded FFR values for the coronary tree, derived from coronary angiogram data, for real-time review and interpretation of possible atherosclerotic stenosis(es) intervention (List separately in addition to code for primary procedure) | Investigational |
| 0524T | Endovenous catheter directed chemical ablation with balloon isolation of incompetent extremity vein, open or percutaneous, including all vascular access, catheter manipulation, diagnostic imaging, imaging guidance and monitoring | Investigational |
| 0525T | Insertion or replacement of intracardiac ischemia monitoring system, including testing of the lead and monitor, initial system programming, and imaging supervision and interpretation; complete system (electrode and implantable monitor) | Investigational |

| | | |
|--------------|--|-----------------|
| 0526T | Insertion or replacement of intracardiac ischemia monitoring system, including testing of the lead and monitor, initial system programming, and imaging supervision and interpretation; electrode only | Investigational |
| 0527T | Insertion or replacement of intracardiac ischemia monitoring system, including testing of the lead and monitor, initial system programming, and imaging supervision and interpretation; implantable monitor only | Investigational |
| 0528T | Programming device evaluation (in person) of intracardiac ischemia monitoring system with iterative adjustment of programmed values, with analysis, review, and report | Investigational |
| 0529T | Interrogation device evaluation (in person) of intracardiac ischemia monitoring system with analysis, review, and report | Investigational |
| 0530T | Removal of intracardiac ischemia monitoring system, including all imaging supervision and interpretation; complete system (electrode and implantable monitor) | Investigational |
| 0531T | Removal of intracardiac ischemia monitoring system, including all imaging supervision and interpretation; electrode only | Investigational |
| 0532T | Removal of intracardiac ischemia monitoring system, including all imaging supervision and interpretation; implantable monitor only | Investigational |
| 0533T | Continuous recording of movement disorder symptoms, including bradykinesia, dyskinesia, and tremor for 6 days up to 10 days; includes set-up, patient training, configuration of monitor, data upload, analysis and initial report configuration, download review, interpretation and report | Investigational |

| | | |
|--------------|---|-----------------|
| 0534T | Continuous recording of movement disorder symptoms, including bradykinesia, dyskinesia, and tremor for 6 days up to 10 days; set-up, patient training, configuration of monitor | Investigational |
| 0535T | Continuous recording of movement disorder symptoms, including bradykinesia, dyskinesia, and tremor for 6 days up to 10 days; data upload, analysis and initial report configuration | Investigational |
| 0536T | Continuous recording of movement disorder symptoms, including bradykinesia, dyskinesia, and tremor for 6 days up to 10 days; download review, interpretation and report | Investigational |
| 0541T | Myocardial imaging by magnetocardiography (MCG) for detection of cardiac ischemia, by signal acquisition using minimum 36 channel grid, generation of magnetic-field time-series images, quantitative analysis of magnetic dipoles, machine learning-derived clinical scoring, and automated report generation, single study; | Investigational |
| 0542T | Myocardial imaging by magnetocardiography (MCG) for detection of cardiac ischemia, by signal acquisition using minimum 36 channel grid, generation of magnetic-field time-series images, quantitative analysis of magnetic dipoles, machine learning-derived clinical scoring, and automated report generation, single study; interpretation and report | Investigational |
| 0543T | Transapical mitral valve repair, including transthoracic echocardiography, when performed, with placement of artificial chordae tendineae | Investigational |

| | | |
|--------------|--|-----------------|
| 0545T | Transcatheter tricuspid valve annulus reconstruction with implantation of adjustable annulus reconstruction device, percutaneous approach | Investigational |
| 0546T | Radiofrequency spectroscopy, real time, intraoperative margin assessment, at the time of partial mastectomy, with report | Investigational |
| 0547T | Bone-material quality testing by microindentation(s) of the tibia(s), with results reported as a score | Investigational |
| 0553T | Percutaneous transcatheter placement of iliac arteriovenous anastomosis implant, inclusive of all radiological supervision and interpretation, intraprocedural roadmapping, and imaging guidance necessary to complete the intervention | Investigational |
| 0554T | Bone strength and fracture risk using finite element analysis of functional data, and bone-mineral density, utilizing data from a computed tomography scan; retrieval and transmission of the scan data, assessment of bone strength and fracture risk and bone mineral density, interpretation and report | Investigational |
| 0555T | Bone strength and fracture risk using finite element analysis of functional data, and bone-mineral density, utilizing data from a computed tomography scan; retrieval and transmission of the scan data | Investigational |
| 0556T | Bone strength and fracture risk using finite element analysis of functional data, and bone-mineral density, utilizing data from a computed tomography scan; assessment of bone strength and fracture risk and bone mineral density | Investigational |

| | | |
|--------------|--|-----------------|
| 0557T | Bone strength and fracture risk using finite element analysis of functional data, and bone-mineral density, utilizing data from a computed tomography scan; interpretation and report | Investigational |
| 0558T | Computed tomography scan taken for the purpose of biomechanical computed tomography analysis | Investigational |
| 0559T | Anatomic model 3D-printed from image data set(s); first individually prepared and processed component of an anatomic structure | Investigational |
| 0560T | Anatomic model 3D-printed from image data set(s); each additional individually prepared and processed component of an anatomic structure (List separately in addition to code for primary procedure) | Investigational |
| 0561T | Anatomic guide 3D-printed and designed from image data set(s); first anatomic guide | Investigational |
| 0562T | Anatomic guide 3D-printed and designed from image data set(s); each additional anatomic guide (List separately in addition to code for primary procedure) | Investigational |
| 0563T | Evacuation of meibomian glands, using heat delivered through wearable, open-eye eyelid treatment devices and manual gland expression, bilateral | Investigational |
| 0564T | Oncology, chemotherapeutic drug cytotoxicity assay of cancer stem cells (CSCs), from cultured CSCs and primary tumor cells, categorical drug response reported based on percent of cytotoxicity observed, a minimum of 14 drugs or drug combinations | Investigational |
| 0565T | Autologous cellular implant derived from adipose tissue for the treatment of osteoarthritis of the knees; tissue harvesting and cellular implant creation | Investigational |

| | | |
|--------------|--|-----------------|
| 0566T | Autologous cellular implant derived from adipose tissue for the treatment of osteoarthritis of the knees; injection of cellular implant into knee joint including ultrasound guidance, unilateral | Investigational |
| 0567T | Permanent fallopian tube occlusion with degradable biopolymer implant, transcervical approach, including transvaginal ultrasound | Investigational |
| 0568T | Introduction of mixture of saline and air for sonosalpingography to confirm occlusion of fallopian tubes, transcervical approach, including transvaginal ultrasound and pelvic ultrasound | Investigational |
| 0569T | Transcatheter tricuspid valve repair, percutaneous approach; initial prosthesis | Investigational |
| 0570T | Transcatheter tricuspid valve repair, percutaneous approach; each additional prosthesis during same session (List separately in addition to code for primary procedure) | Investigational |
| 0581T | Ablation, malignant breast tumor(s), percutaneous, cryotherapy, including imaging guidance when performed, unilateral | Investigational |
| 0582T | Transurethral ablation of malignant prostate tissue by high-energy water vapor thermotherapy, including intraoperative imaging and needle guidance | Investigational |
| 0583T | Tympanostomy (requiring insertion of ventilating tube), using an automated tube delivery system, iontophoresis local anesthesia | Investigational |
| 0587T | Percutaneous implantation or replacement of integrated single device neurostimulation system including electrode array and receiver or pulse generator, including analysis, programming, and imaging guidance when performed, posterior tibial nerve | Investigational |

| | | |
|--------------|---|-----------------|
| 0588T | Revision or removal of integrated single device neurostimulation system including electrode array and receiver or pulse generator, including analysis, programming, and imaging guidance when performed, posterior tibial nerve | Investigational |
| 0589T | Electronic analysis with simple programming of implanted integrated neurostimulation system (eg, electrode array and receiver), including contact group(s), amplitude, pulse width, frequency (Hz), on/off cycling, burst, dose lockout, patient-selectable parameters, responsive neurostimulation, detection algorithms, closed-loop parameters, and passive parameters, when performed by physician or other qualified health care professional, posterior tibial nerve, 1-3 parameters | Investigational |
| 0590T | Electronic analysis with complex programming of implanted integrated neurostimulation system (eg, electrode array and receiver), including contact group(s), amplitude, pulse width, frequency (Hz), on/off cycling, burst, dose lockout, patient-selectable parameters, responsive neurostimulation, detection algorithms, closed-loop parameters, and passive parameters, when performed by physician or other qualified health care professional, posterior tibial nerve, 4 or more parameters | Investigational |
| 0594T | Osteotomy, humerus, with insertion of an externally controlled intramedullary lengthening device, including intraoperative imaging, initial and subsequent alignment assessments, computations of adjustment schedules, and management of the intramedullary lengthening device | Investigational |

| | | |
|--------------|---|-----------------|
| 0596T | Temporary female intraurethral valve-pump (ie, voiding prosthesis); initial insertion, including urethral measurement | Investigational |
| 0597T | Temporary female intraurethral valve-pump (ie, voiding prosthesis); replacement | Investigational |
| 0598T | Noncontact real-time fluorescence wound imaging, for bacterial presence, location, and load, per session; first anatomic site (eg, lower extremity) | Investigational |
| 0599T | Noncontact real-time fluorescence wound imaging, for bacterial presence, location, and load, per session; each additional anatomic site (eg, upper extremity) (List separately in addition to code for primary procedure) | Investigational |
| 0602T | Glomerular filtration rate (GFR) measurement(s), transdermal, including sensor placement and administration of a single dose of fluorescent pyrazine agent | Investigational |
| 0603T | Glomerular filtration rate (GFR) monitoring, transdermal, including sensor placement and administration of more than one dose of fluorescent pyrazine agent, each 24 hours | Investigational |
| 0604T | Optical coherence tomography (OCT) of retina, remote, patient-initiated image capture and transmission to a remote surveillance center unilateral or bilateral; initial device provision, set-up and patient education on use of equipment | Investigational |
| 0605T | Optical coherence tomography (OCT) of retina, remote, patient-initiated image capture and transmission to a remote surveillance center unilateral or bilateral; remote surveillance center technical support, data analyses and reports, with a minimum of 8 daily recordings, each 30 days | Investigational |

| | | |
|--------------|--|-----------------|
| 0606T | Optical coherence tomography (OCT) of retina, remote, patient-initiated image capture and transmission to a remote surveillance center unilateral or bilateral; review, interpretation and report by the prescribing physician or other qualified health care professional of remote surveillance center data analyses, each 30 days | Investigational |
| 0607T | Remote monitoring of an external continuous pulmonary fluid monitoring system, including measurement of radiofrequency-derived pulmonary fluid levels, heart rate, respiration rate, activity, posture, and cardiovascular rhythm (eg, ECG data), transmitted to a remote 24-hour attended surveillance center; set-up and patient education on use of equipment | Investigational |
| 0608T | Remote monitoring of an external continuous pulmonary fluid monitoring system, including measurement of radiofrequency-derived pulmonary fluid levels, heart rate, respiration rate, activity, posture, and cardiovascular rhythm (eg, ECG data), transmitted to a remote 24-hour attended surveillance center; analysis of data received and transmission of reports to the physician or other qualified health care professional | Investigational |
| 0609T | Magnetic resonance spectroscopy, determination and localization of discogenic pain (cervical, thoracic, or lumbar); acquisition of single voxel data, per disc, on biomarkers (ie, lactic acid, carbohydrate, alanine, laal, propionic acid, proteoglycan, and collagen) in at least 3 discs | Investigational |

| | | |
|--------------|--|-----------------|
| 0610T | Magnetic resonance spectroscopy, determination and localization of discogenic pain (cervical, thoracic, or lumbar); transmission of biomarker data for software analysis | Investigational |
| 0611T | Magnetic resonance spectroscopy, determination and localization of discogenic pain (cervical, thoracic, or lumbar); postprocessing for algorithmic analysis of biomarker data for determination of relative chemical differences between discs | Investigational |
| 0612T | Magnetic resonance spectroscopy, determination and localization of discogenic pain (cervical, thoracic, or lumbar); interpretation and report | Investigational |
| 0613T | Percutaneous transcatheter implantation of interatrial septal shunt device, including right and left heart catheterization, intracardiac echocardiography, and imaging guidance by the proceduralist, when performed | Investigational |
| 0614T | Removal and replacement of substernal implantable defibrillator pulse generator | Investigational |
| 0615T | Eye-movement analysis without spatial calibration, with interpretation and report | Investigational |
| 0619T | Cystourethroscopy with transurethral anterior prostate commissurotomy and drug delivery, including transrectal ultrasound and fluoroscopy, when performed | Investigational |

| | | |
|--------------|--|-----------------|
| 0620T | Endovascular venous arterialization, tibial or peroneal vein, with transcatheter placement of intravascular stent graft(s) and closure by any method, including percutaneous or open vascular access, ultrasound guidance for vascular access when performed, all catheterization(s) and intraprocedural roadmapping and imaging guidance necessary to complete the intervention, all associated radiological supervision and interpretation, when performed | Investigational |
| 0621T | Trabeculostomy ab interno by laser | Investigational |
| 0622T | Trabeculostomy ab interno by laser; with use of ophthalmic endoscope | Investigational |
| 0623T | Automated quantification and characterization of coronary atherosclerotic plaque to assess severity of coronary disease, using data from coronary computed tomographic angiography; data preparation and transmission, computerized analysis of data, with review of computerized analysis output to reconcile discordant data, interpretation and report | Investigational |
| 0624T | Automated quantification and characterization of coronary atherosclerotic plaque to assess severity of coronary disease, using data from coronary computed tomographic angiography; data preparation and transmission | Investigational |
| 0625T | Automated quantification and characterization of coronary atherosclerotic plaque to assess severity of coronary disease, using data from coronary computed tomographic angiography; computerized analysis of data from coronary computed tomographic angiography | Investigational |

| | | |
|--------------|--|-----------------|
| 0626T | Automated quantification and characterization of coronary atherosclerotic plaque to assess severity of coronary disease, using data from coronary computed tomographic angiography; review of computerized analysis output to reconcile discordant data, interpretation and report | Investigational |
| 0627T | Percutaneous injection of allogeneic cellular and/or tissue-based product, intervertebral disc, unilateral or bilateral injection, with fluoroscopic guidance, lumbar; first level | Investigational |
| 0628T | Percutaneous injection of allogeneic cellular and/or tissue-based product, intervertebral disc, unilateral or bilateral injection, with fluoroscopic guidance, lumbar; each additional level (List separately in addition to code for primary procedure) | Investigational |
| 0629T | Percutaneous injection of allogeneic cellular and/or tissue-based product, intervertebral disc, unilateral or bilateral injection, with CT guidance, lumbar; first level | Investigational |
| 0630T | Percutaneous injection of allogeneic cellular and/or tissue-based product, intervertebral disc, unilateral or bilateral injection, with CT guidance, lumbar; each additional level (List separately in addition to code for primary procedure) | Investigational |
| 0631T | Transcutaneous visible light hyperspectral imaging measurement of oxyhemoglobin, deoxyhemoglobin, and tissue oxygenation, with interpretation and report, per extremity | Investigational |
| 0632T | Percutaneous transcatheter ultrasound ablation of nerves innervating the pulmonary arteries, including right heart catheterization, pulmonary artery angiography, and all imaging guidance | Investigational |

| | | |
|--------------|---|-----------------|
| 0633T | Computed tomography, breast, including 3D rendering, when performed, unilateral; without contrast material | Investigational |
| 0634T | Computed tomography, breast, including 3D rendering, when performed, unilateral; with contrast material(s) | Investigational |
| 0635T | Computed tomography, breast, including 3D rendering, when performed, unilateral; without contrast, followed by contrast material(s) | Investigational |
| 0636T | Computed tomography, breast, including 3D rendering, when performed, bilateral; without contrast material(s) | Investigational |
| 0637T | Computed tomography, breast, including 3D rendering, when performed, bilateral; with contrast material(s) | Investigational |
| 0638T | Computed tomography, breast, including 3D rendering, when performed, bilateral; without contrast, followed by contrast material(s) | Investigational |
| 0639T | Wireless skin sensor thermal anisotropy measurement(s) and assessment of flow in cerebrospinal fluid shunt, including ultrasound guidance, when performed | Investigational |
| 0640T | Noncontact near-infrared spectroscopy studies of flap or wound (eg, for measurement of deoxyhemoglobin, oxyhemoglobin, and ratio of tissue oxygenation [StO ₂]); image acquisition, interpretation and report, each flap or wound | Investigational |
| 0641T | Noncontact near-infrared spectroscopy studies of flap or wound (eg, for measurement of deoxyhemoglobin, oxyhemoglobin, and ratio of tissue oxygenation [StO ₂]); image acquisition only, each flap or wound | Investigational |

| | | |
|--------------|---|-----------------|
| 0642T | Noncontact near-infrared spectroscopy studies of flap or wound (eg, for measurement of deoxyhemoglobin, oxyhemoglobin, and ratio of tissue oxygenation [StO2]); interpretation and report only, each flap or wound | Investigational |
| 0643T | Transcatheter left ventricular restoration device implantation including right and left heart catheterization and left ventriculography when performed, arterial approach | Investigational |
| 0646T | Transcatheter tricuspid valve implantation (TTVI)/replacement with prosthetic valve, percutaneous approach, including right heart catheterization, temporary pacemaker insertion, and selective right ventricular or right atrial angiography, when performed | Investigational |
| 0647T | Insertion of gastrostomy tube, percutaneous, with magnetic gastropexy, under ultrasound guidance, image documentation and report | Investigational |
| 0651T | Magnetically controlled capsule endoscopy, esophagus through stomach, including intraprocedural positioning of capsule, with interpretation and report | Investigational |
| 0652T | Esophagogastroduodenoscopy, flexible, transnasal; diagnostic, including collection of specimen(s) by brushing or washing, when performed (separate procedure) | Investigational |
| 0653T | Esophagogastroduodenoscopy, flexible, transnasal; with biopsy, single or multiple | Investigational |
| 0654T | Esophagogastroduodenoscopy, flexible, transnasal; with insertion of intraluminal tube or catheter | Investigational |

| | | |
|--------------|--|-----------------|
| 0655T | Transperineal focal laser ablation of malignant prostate tissue, including transrectal imaging guidance, with MR-fused images or other enhanced ultrasound imaging | Investigational |
| 0656T | Vertebral body tethering, anterior; up to 7 vertebral segments | Investigational |
| 0657T | Vertebral body tethering, anterior; 8 or more vertebral segments | Investigational |
| 0658T | Electrical impedance spectroscopy of 1 or more skin lesions for automated melanoma risk score | Investigational |
| 0659T | Transcatheter intracoronary infusion of supersaturated oxygen in conjunction with percutaneous coronary revascularization during acute myocardial infarction, including catheter placement, imaging guidance (eg, fluoroscopy), angiography, and radiologic supervision and interpretation | Investigational |
| 0660T | Implantation of anterior segment intraocular nonbiodegradable drug-eluting system, internal approach | Investigational |
| 0661T | Removal and reimplantation of anterior segment intraocular nonbiodegradable drug-eluting implant | Investigational |
| 0664T | Donor hysterectomy (including cold preservation); open, from cadaver donor | Investigational |
| 0665T | Donor hysterectomy (including cold preservation); open, from living donor | Investigational |
| 0666T | Donor hysterectomy (including cold preservation); laparoscopic or robotic, from living donor | Investigational |
| 0667T | Donor hysterectomy (including cold preservation); recipient uterus allograft transplantation from cadaver or living donor | Investigational |

| | | |
|--------------|--|-----------------|
| 0668T | Backbench standard preparation of cadaver or living donor uterine allograft prior to transplantation, including dissection and removal of surrounding soft tissues and preparation of uterine vein(s) and uterine artery(ies), as necessary | Investigational |
| 0669T | Backbench reconstruction of cadaver or living donor uterus allograft prior to transplantation; venous anastomosis, each | Investigational |
| 0670T | Backbench reconstruction of cadaver or living donor uterus allograft prior to transplantation; arterial anastomosis, each | Investigational |
| 0672T | Endovaginal cryogen-cooled, monopolar radiofrequency remodeling of the tissues surrounding the female bladder neck and proximal urethra for urinary incontinence | Investigational |
| 0673T | Ablation, benign thyroid nodule(s), percutaneous, laser, including imaging guidance | Investigational |
| 0674T | Laparoscopic insertion of new or replacement of permanent implantable synchronized diaphragmatic stimulation system for augmentation of cardiac function, including an implantable pulse generator and diaphragmatic lead(s) | Investigational |
| 0675T | Laparoscopic insertion of new or replacement of diaphragmatic lead(s), permanent implantable synchronized diaphragmatic stimulation system for augmentation of cardiac function, including connection to an existing pulse generator; first lead | Investigational |

| | | |
|--------------|--|-----------------|
| 0676T | Laparoscopic insertion of new or replacement of diaphragmatic lead(s), permanent implantable synchronized diaphragmatic stimulation system for augmentation of cardiac function, including connection to an existing pulse generator; each additional lead (List separately in addition to code for primary procedure) | Investigational |
| 0677T | Laparoscopic repositioning of diaphragmatic lead(s), permanent implantable synchronized diaphragmatic stimulation system for augmentation of cardiac function, including connection to an existing pulse generator; first repositioned lead | Investigational |
| 0678T | Laparoscopic repositioning of diaphragmatic lead(s), permanent implantable synchronized diaphragmatic stimulation system for augmentation of cardiac function, including connection to an existing pulse generator; each additional repositioned lead (List separately in addition to code for primary procedure) | Investigational |
| 0679T | Laparoscopic removal of diaphragmatic lead(s), permanent implantable synchronized diaphragmatic stimulation system for augmentation of cardiac function | Investigational |
| 0680T | Insertion or replacement of pulse generator only, permanent implantable synchronized diaphragmatic stimulation system for augmentation of cardiac function, with connection to existing lead(s) | Investigational |
| 0681T | Relocation of pulse generator only, permanent implantable synchronized diaphragmatic stimulation system for augmentation of cardiac function, with connection to existing dual leads | Investigational |

| | | |
|--------------|---|-----------------|
| 0682T | Relocation of pulse generator only, permanent implantable synchronized diaphragmatic stimulation system for augmentation of cardiac function, with connection to existing dual leads | Investigational |
| 0683T | Programming device evaluation (in-person) with iterative adjustment of the implantable device to test the function of the device and select optimal permanent programmed values with analysis, review and report by a physician or other qualified health care professional, permanent implantable synchronized diaphragmatic stimulation system for augmentation of cardiac function | Investigational |
| 0684T | Peri-procedural device evaluation (in-person) and programming of device system parameters before or after a surgery, procedure, or test with analysis, review, and report by a physician or other qualified health care professional, permanent implantable synchronized diaphragmatic stimulation system for augmentation of cardiac function | Investigational |
| 0685T | Interrogation device evaluation (in-person) with analysis, review and report by a physician or other qualified health care professional, including connection, recording and disconnection per patient encounter, permanent implantable synchronized diaphragmatic stimulation system for augmentation of cardiac function | Investigational |
| 0686T | Histotripsy (ie, non-thermal ablation via acoustic energy delivery) of malignant hepatocellular tissue, including image guidance | Investigational |

| | | |
|--------------|--|-----------------|
| 0687T | Treatment of amblyopia using an online digital program; device supply, educational set-up, and initial session | Investigational |
| 0688T | Treatment of amblyopia using an online digital program; assessment of patient performance and program data by physician or other qualified health care professional, with report, per calendar month | Investigational |
| 0689T | Quantitative ultrasound tissue characterization (non-elastographic), including interpretation and report, obtained without diagnostic ultrasound examination of the same anatomy (eg, organ, gland, tissue, target structure) | Investigational |
| 0690T | Quantitative ultrasound tissue characterization (non-elastographic), including interpretation and report, obtained with diagnostic ultrasound examination of the same anatomy (eg, organ, gland, tissue, target structure) (List separately in addition to code for primary procedure) | Investigational |
| 0691T | Automated analysis of an existing computed tomography study for vertebral fracture(s), including assessment of bone density when performed, data preparation, interpretation, and report | Investigational |
| 0693T | Comprehensive full body computer-based markerless 3D kinematic and kinetic motion analysis and report | Investigational |
| 0694T | 3-dimensional volumetric imaging and reconstruction of breast or axillary lymph node tissue, each excised specimen, 3-dimensional automatic specimen reorientation, interpretation and report, real-time intraoperative | Investigational |

| | | |
|--------------|---|-----------------|
| 0695T | Body surface-activation mapping of pacemaker or pacing cardioverter-defibrillator lead(s) to optimize electrical synchrony, cardiac resynchronization therapy device, including connection, recording, disconnection, review, and report; at time of implant or replacement | Investigational |
| 0696T | Body surface-activation mapping of pacemaker or pacing cardioverter-defibrillator lead(s) to optimize electrical synchrony, cardiac resynchronization therapy device, including connection, recording, disconnection, review, and report; at time of follow-up interrogation or programming device evaluation | Investigational |
| 0697T | Quantitative magnetic resonance for analysis of tissue composition (eg, fat, iron, water content), including multiparametric data acquisition, data preparation and transmission, interpretation and report, obtained without diagnostic MRI examination of the same anatomy (eg, organ, gland, tissue, target structure) during the same session; multiple organs | Investigational |
| 0698T | Quantitative magnetic resonance for analysis of tissue composition (eg, fat, iron, water content), including multiparametric data acquisition, data preparation and transmission, interpretation and report, obtained with diagnostic MRI examination of the same anatomy (eg, organ, gland, tissue, target structure); multiple organs (List separately in addition to code for primary procedure) | Investigational |
| 0700T | Molecular fluorescent imaging of suspicious nevus; first lesion | Investigational |
| 0701T | Molecular fluorescent imaging of suspicious nevus; each additional lesion (List separately in addition to code for primary procedure) | Investigational |

| | | |
|--------------|---|-----------------|
| 0704T | Remote treatment of amblyopia using an eye tracking device; device supply with initial set-up and patient education on use of equipment | Investigational |
| 0705T | Remote treatment of amblyopia using an eye tracking device; surveillance center technical support including data transmission with analysis, with a minimum of 18 training hours, each 30 days | Investigational |
| 0706T | Remote treatment of amblyopia using an eye tracking device; interpretation and report by physician or other qualified health care professional, per calendar month | Investigational |
| 0707T | Injection(s), bone substitute material (eg, calcium phosphate) into subchondral bone defect (ie, bone marrow lesion, bone bruise, stress injury, microtrabecular fracture), including imaging guidance and arthroscopic assistance for joint visualization | Investigational |
| 0708T | Intradermal cancer immunotherapy; preparation and initial injection | Investigational |
| 0709T | Intradermal cancer immunotherapy; each additional injection (List separately in addition to code for primary procedure) | Investigational |
| 0710T | Noninvasive arterial plaque analysis using software processing of data from non-coronary computerized tomography angiography; including data preparation and transmission, quantification of the structure and composition of the vessel wall and assessment for lipid-rich necrotic core plaque to assess atherosclerotic plaque stability, data review, interpretation and report | Investigational |
| 0711T | Noninvasive arterial plaque analysis using software processing of data from non-coronary computerized tomography angiography; data preparation and transmission | Investigational |

| | | |
|--------------|--|-----------------|
| 0712T | Noninvasive arterial plaque analysis using software processing of data from non-coronary computerized tomography angiography; quantification of the structure and composition of the vessel wall and assessment for lipid-rich necrotic core plaque to assess atherosclerotic plaque stability | Investigational |
| 0713T | Noninvasive arterial plaque analysis using software processing of data from non-coronary computerized tomography angiography; data review, interpretation and report | Investigational |
| 0714T | Transperineal laser ablation of benign prostatic hyperplasia, including imaging guidance | Investigational |
| 0715T | "Percutaneous transluminal coronary lithotripsy (List separately in addition to code for primary procedure)" | Investigational |
| 0716T | Cardiac acoustic waveform recording with automated analysis and generation of coronary artery disease risk score | Investigational |
| 0717T | "Autologous adipose-derived regenerative cell (ADRC) therapy for partial thickness rotator cuff tear; adipose tissue harvesting, isolation and preparation of harvested cells, including incubation with cell dissociation enzymes, filtration, washing and concentration of ADRCs | Investigational |
| 0718T | Autologous adipose-derived regenerative cell (ADRC) therapy for partial thickness rotator cuff tear; injection into supraspinatus tendon including ultrasound guidance, unilateral | Investigational |
| 0719T | "Posterior vertebral joint replacement, including bilateral facetectomy, laminectomy, and radical discectomy, including imaging guidance, lumbar spine, single segment | Investigational |

| | | |
|--------------|--|-----------------|
| 0720T | Percutaneous electrical nerve field stimulation, cranial nerves, without implantation | Investigational |
| 0721T | "Quantitative computed tomography (CT) tissue characterization, including interpretation and report, obtained without concurrent CT examination of any structure contained in previously acquired diagnostic imaging | Investigational |
| 0722T | "Quantitative computed tomography (CT) tissue characterization, including interpretation and report, obtained with concurrent CT examination of any structure contained in the concurrently acquired diagnostic imaging dataset (List separately in addition to code for primary procedure) | Investigational |
| 0723T | "Quantitative magnetic resonance cholangiopancreatography (QMRCP) including data preparation and transmission, interpretation and report, obtained without diagnostic magnetic resonance imaging (MRI) examination of the same anatomy (eg, organ, gland, tissue, target structure) during the same session | Investigational |
| 0724T | "Quantitative magnetic resonance cholangiopancreatography (QMRCP) including data preparation and transmission, interpretation and report, obtained with diagnostic magnetic resonance imaging (MRI) examination of the same anatomy (eg, organ, gland, tissue, target structure) (List separately in addition to code for primary procedure) | Investigational |
| 0725T | Vestibular device implantation, unilateral | Investigational |
| 0726T | Removal of implanted vestibular device, unilateral | Investigational |

| | | |
|--------------|---|-----------------|
| 0727T | Removal and replacement of implanted vestibular device, unilateral | Investigational |
| 0728T | Diagnostic analysis of vestibular implant, unilateral; with initial programming | Investigational |
| 0729T | with subsequent programming (For initial and subsequent diagnostic analysis and programming of cochlear implant | Investigational |
| 0730T | Trabeculotomy by laser, including optical coherence tomography (OCT) guidance | Investigational |
| 0731T | Augmentative AI-based facial phenotype analysis with report | Investigational |
| 0732T | Immunotherapy administration with electroporation, intramuscular | Investigational |
| 0733T | Remote therapy ordered by a physician or other qualified health care professional; supply and technical support, per 30 days | Investigational |
| 0734T | Remote body and limb kinematic measurement-based therapy ordered by a physician or other qualified health care professional; supply and technical support, per 30 days; treatment management services by a physician or other qualified health care professional, per calendar month" | Investigational |
| 0735T | "Preparation of tumor cavity, with placement of a radiation therapy applicator for intraoperative radiation therapy (IORT) concurrent with primary craniotomy (List separately in addition to code for primary procedure) | Investigational |
| 0736T | Colonic lavage, 35 or more liters of water, gravity-fed, with induced defecation, including insertion of rectal catheter | Investigational |
| 0737T | Xenograft implantation into the articular surface | Investigational |

| | | |
|--------------|---|-----------------|
| 0738T | Treatment planning for magnetic field induction ablation of malignant prostate tissue, using data from previously performed magnetic resonance imaging (MRI) examination | Investigational |
| 0739T | Ablation of malignant prostate tissue by magnetic field induction, including all intraprocedural, transperineal needle/catheter placement for nanoparticle installation and intraprocedural temperature monitoring, thermal dosimetry, bladder irrigation, and magnetic field nanoparticle activation | Investigational |
| 0740T | Remote autonomous algorithm-based recommendation system for insulin dose calculation and titration; initial set-up and patient education | Investigational |
| 0741T | Remote autonomous algorithm-based recommendation system for insulin dose calculation and titration; initial set-up and patient education; provision of software, data collection, transmission, and storage, each 30 days | Investigational |
| 0742T | Absolute quantitation of myocardial blood flow (AQMBF), single-photon emission computed tomography (SPECT), with exercise or pharmacologic stress, and at rest, when performed (List separately in addition to code for primary procedure) | Investigational |

| | | |
|--------------|--|-----------------|
| 0743T | Bone strength and fracture risk using finite element analysis of functional data and bone-mineral density, with concurrent vertebral fracture assessment, utilizing data from a computed tomography scan, retrieval and transmission of the scan data, measurement of bone strength and bone mineral density and classification of any vertebral fractures, with overall fracture risk assessment, interpretation and report | Investigational |
| 0744T | Insertion of bioprosthetic valve, open, femoral vein, including duplex ultrasound imaging guidance, when performed, including autogenous or nonautogenous patch graft (eg, polyester, ePTFE, bovine pericardium), when performed | Investigational |
| 0745T | Cardiac focal ablation utilizing radiation therapy for arrhythmia; noninvasive arrhythmia localization and mapping of arrhythmia site (nidus), derived from anatomical image data (eg, CT, MRI, or myocardial perfusion scan) and electrical data (eg, 12-lead ECG data), and identification of areas of avoidance | Investigational |
| 0746T | Cardiac focal ablation utilizing radiation therapy for arrhythmia; conversion of arrhythmia localization and mapping of arrhythmia site (nidus) into a multidimensional radiation treatment plan | Investigational |
| 0747T | Cardiac focal ablation utilizing radiation therapy for arrhythmia; delivery of radiation therapy, arrhythmia | Investigational |
| 0748T | Injections of stem cell product into perianal perirectal soft tissue, including fistula preparation (eg, removal of setons, fistula curettage, closure of internal openings) | Investigational |

| | | |
|--------------|---|-----------------|
| 0749T | Bone strength and fracture-risk assessment using digital X-ray radiogrammetrybone mineral density (DXR-BMD) analysis of bone mineral density (BMD) utilizing data from a digital X ray, retrieval and transmission of digital X ray data, assessment of bone strength and fracture-risk and BMD, interpretation and report | Investigational |
| 0750T | Bone strength and fracture-risk assessment using digital X-ray radiogrammetrybone mineral density (DXR-BMD) analysis of bone mineral density (BMD) utilizing data from a digital X ray, retrieval and transmission of digital X ray data, assessment of bone strength and fracture-risk and BMD, interpretation and report; with single-view digital X-ray examination of the hand taken for the purpose of DXR-BMD | Investigational |
| 0751T | Digitization of glass microscope slides for level II, surgical pathology, gross and microscopic examination (List separately in addition to code for primary procedure) | Investigational |
| 0752T | Digitization of glass microscope slides for level III, surgical pathology, gross and microscopic examination (List separately in addition to code for primary procedure) | Investigational |
| 0753T | Digitization of glass microscope slides for level IV, surgical pathology, gross and microscopic examination (List separately in addition to code for primary procedure) | Investigational |
| 0754T | Digitization of glass microscope slides for level V, surgical pathology, gross and microscopic examination (List separately in addition to code for primary procedure) | Investigational |

| | | |
|--------------|---|-----------------|
| 0755T | Digitization of glass microscope slide for level VI, surgical pathology, gross and microscopic examination (List separately in addition to code for primary procedure) | Investigational |
| 0756T | Digitization of glass microscope slides for special stain, including interpretation and report, group I, for microorganisms (eg, acid fast, methenamine silver) (List separately in addition to code for primary procedure) | Investigational |
| 0757T | Digitization of glass microscope slides for special stain, including interpretation and report, group II, all other (eg, iron, trichrome), except stain for microorganisms, stains for enzyme constituents, or immunocytochemistry and immunohistochemistry (List separately in addition to code for primary procedure) | Investigational |
| 0758T | Digitization of glass microscope slides for special stain, including interpretation and report, histochemical stain on frozen tissue block (List separately in addition to code for primary procedure) | Investigational |
| 0759T | Digitization of glass microscope slides for special stain, including interpretation and report, group III, for enzyme constituents (List separately in addition to code for primary procedure) | Investigational |
| 0760T | Digitization of glass microscope slides for immunohistochemistry or immunocytochemistry, per specimen, initial single antibody stain procedure (List separately in addition to code for primary procedure) | Investigational |

| | | |
|--------------|--|-----------------|
| 0761T | Digitization of glass microscope slides for immunohistochemistry or immunocytochemistry, per specimen, each additional single antibody stain procedure (List separately in addition to code for primary procedure) | Investigational |
| 0762T | Digitization of glass microscope slides for immunohistochemistry or immunocytochemistry, per specimen, each multiplex antibody stain procedure (List separately in addition to code for primary procedure) | Investigational |
| 0763T | Digitization of glass microscope slides for morphometric analysis, tumor immunohistochemistry (eg, Her-2/neu, estrogen receptor/progesterone receptor), quantitative or semiquantitative, per specimen, each single antibody stain procedure, manual (List separately in addition to code for primary procedure) | Investigational |
| 0764T | Assistive algorithmic electrocardiogram risk-based assessment for cardiac dysfunction (eg, low-ejection fraction, pulmonary hypertension, hypertrophic cardiomyopathy); related to concurrently performed electrocardiogram (List separately in addition to code for primary procedure) | Investigational |
| 0765T | Assistive algorithmic electrocardiogram risk-based assessment for cardiac dysfunction (eg, low-ejection fraction, pulmonary hypertension, hypertrophic cardiomyopathy); related to previously performed electrocardiogram | Investigational |

| | | |
|--------------|---|-----------------|
| 0766T | Transcutaneous magnetic stimulation by focused low-frequency electromagnetic pulse, peripheral nerve, initial treatment, with identification and marking of the treatment location, including noninvasive electroneurographic localization (nerve conduction localization), when performed; first nerve | Investigational |
| 0767T | Transcutaneous magnetic stimulation by focused low-frequency electromagnetic pulse, peripheral nerve, initial treatment, with identification and marking of the treatment location, including noninvasive electroneurographic localization (nerve conduction localization), when performed; each additional nerve (List separately in addition to code for primary procedure) | Investigational |
| 0768T | Transcutaneous magnetic stimulation by focused low-frequency electromagnetic pulse, peripheral nerve, subsequent treatment, including noninvasive electroneurographic localization (nerve conduction localization), when performed; first nerve | Investigational |
| 0769T | Transcutaneous magnetic stimulation by focused low-frequency electromagnetic pulse, peripheral nerve, subsequent treatment, including noninvasive electroneurographic localization (nerve conduction localization), when performed; each additional nerve (List separately in addition to code for primary procedure) | Investigational |
| 0770T | Virtual reality technology to assist therapy (List separately in addition to code for primary procedure) | Investigational |

| | | |
|--------------|---|-----------------|
| 0771T | Virtual reality (VR) procedural dissociation services provided by the same physician or other qualified health care professional performing the diagnostic or therapeutic service that the VR procedural dissociation supports, requiring the presence of an independent, trained observer to assist in the monitoring of the patient's level of dissociation or consciousness and physiological status; initial 15 minutes of intraservice time, patient age 5 years or older | Investigational |
| 0772T | Virtual reality (VR) procedural dissociation services provided by the same physician or other qualified health care professional performing the diagnostic or therapeutic service that the VR procedural dissociation supports, requiring the presence of an independent, trained observer to assist in the monitoring of the patient's level of dissociation or consciousness and physiological status; each additional 15 minutes intraservice time (List separately in addition to code for primary service) | Investigational |
| 0773T | Virtual reality (VR) procedural dissociation services provided by a physician or other qualified health care professional other than the physician or other qualified health care professional performing the diagnostic or therapeutic service that the VR procedural dissociation supports; initial 15 minutes of intraservice time, patient age 5 years or older | Investigational |

| | | |
|--------------|--|-----------------|
| 0774T | Virtual reality (VR) procedural dissociation services provided by a physician or other qualified health care professional other than the physician or other qualified health care professional performing the diagnostic or therapeutic service that the VR procedural dissociation supports; each additional 15 minutes intraservice time (List separately in addition to code for primary service) | Investigational |
| 0775T | Arthrodesis, sacroiliac joint, percutaneous, with image guidance, includes placement of intra-articular implant(s) (eg, bone allograft[s], synthetic device[s]) | Investigational |
| 0776T | Therapeutic induction of intra-brain hypothermia, including placement of a mechanical temperature-controlled cooling device to the neck over carotids and head, including monitoring (eg, vital signs and sport concussion assessment tool 5 [SCAT5]), 30 minutes of treatment | Investigational |
| 0777T | Real-time pressure-sensing epidural guidance system (List separately in addition to code for primary procedure) | Investigational |
| 0778T | Surface mechanomyography (sMMG) with concurrent application of inertial measurement unit (IMU) sensors for measurement of multi-joint range of motion, posture, gait, and muscle function | Investigational |
| 0779T | Gastrointestinal myoelectrical activity study, stomach through colon, with interpretation and report | Investigational |
| 0780T | Instillation of fecal microbiota suspension via rectal enema into lower gastrointestinal tract | Investigational |

| | | |
|--------------|---|-----------------|
| 0781T | Bronchoscopy, rigid or flexible, with insertion of esophageal protection device and circumferential radiofrequency destruction of the pulmonary nerves, including fluoroscopic guidance when performed; bilateral mainstem bronchi | Investigational |
| 0782T | Bronchoscopy, rigid or flexible, with insertion of esophageal protection device and circumferential radiofrequency destruction of the pulmonary nerves, including fluoroscopic guidance when performed; unilateral mainstem bronchus | Investigational |
| 0783T | Transcutaneous auricular neurostimulation, set-up, calibration, and patient education on use of equipment | Investigational |
| 0791T | Motor-cognitive, semi-immersive virtual reality-facilitated gait training, each 15 minutes (List separately in addition to code for primary procedure) | Investigational |
| 0792T | Application of silver diamine fluoride 38%, by a physician or other qualified health care professional | Investigational |
| 0793T | Percutaneous transcatheter thermal ablation of nerves innervating the pulmonary arteries, including right heart catheterization, pulmonary artery angiography, and all imaging guidance | Investigational |
| 0794T | Patient-specific, assistive, rules-based algorithm for ranking pharmaco-oncologic treatment options based on the patient's tumor-specific cancer marker information obtained from prior molecular pathology, immunohistochemical, or other pathology results which have been previously interpreted and reported separately | Investigational |

| | | |
|--------------|---|-----------------|
| 0795T | Transcatheter insertion of permanent dual-chamber leadless pacemaker, including imaging guidance (e.g., fluoroscopy, venous ultrasound, right atrial angiography, right ventriculography, femoral venography) and device evaluation (e.g., interrogation or programming), when performed; complete system (i.e., right atrial and right ventricular pacemaker components) | Investigational |
| 0796T | Transcatheter insertion of permanent dual-chamber leadless pacemaker, including imaging guidance (e.g., fluoroscopy, venous ultrasound, right atrial angiography, right ventriculography, femoral venography) and device evaluation (e.g., interrogation or programming), when performed; right atrial pacemaker component (when an existing right ventricular single leadless pacemaker exists to create a dual-chamber leadless pacemaker system) | Investigational |
| 0797T | Transcatheter insertion of permanent dual-chamber leadless pacemaker, including imaging guidance (e.g., fluoroscopy, venous ultrasound, right atrial angiography, right ventriculography, femoral venography) and device evaluation (e.g., interrogation or programming), when performed; right ventricular pacemaker component (when part of a dual-chamber leadless pacemaker system) | Investigational |

| | | |
|--------------|---|-----------------|
| 0798T | Transcatheter removal of permanent dual-chamber leadless pacemaker, including imaging guidance (e.g., fluoroscopy, venous ultrasound, right atrial angiography, right ventriculography, femoral venography), when performed; complete system (i.e., right atrial and right ventricular pacemaker components) | Investigational |
| 0799T | Transcatheter removal of permanent dual-chamber leadless pacemaker, including imaging guidance (e.g., fluoroscopy, venous ultrasound, right atrial angiography, right ventriculography, femoral venography), when performed; right atrial pacemaker component | Investigational |
| 0800T | Transcatheter removal of permanent dual-chamber leadless pacemaker, including imaging guidance (e.g., fluoroscopy, venous ultrasound, right atrial angiography, right ventriculography, femoral venography), when performed; right ventricular pacemaker component (when part of a dual-chamber leadless pacemaker system) | Investigational |
| 0801T | Transcatheter removal and replacement of permanent dual-chamber leadless pacemaker, including imaging guidance (e.g., fluoroscopy, venous ultrasound, right atrial angiography, right ventriculography, femoral venography) and device evaluation (e.g., interrogation or programming), when performed; dual-chamber system (i.e., right atrial and right ventricular pacemaker components) | Investigational |

| | | |
|--------------|---|-----------------|
| 0802T | Transcatheter removal and replacement of permanent dual-chamber leadless pacemaker, including imaging guidance (e.g., fluoroscopy, venous ultrasound, right atrial angiography, right ventriculography, femoral venography) and device evaluation (e.g., interrogation or programming), when performed; right atrial pacemaker component | Investigational |
| 0803T | Transcatheter removal and replacement of permanent dual-chamber leadless pacemaker, including imaging guidance (e.g., fluoroscopy, venous ultrasound, right atrial angiography, right ventriculography, femoral venography) and device evaluation (e.g., interrogation or programming), when performed; right ventricular pacemaker component (when part of a dual-chamber leadless pacemaker system) | Investigational |
| 0804T | Programming device evaluation (in person) with iterative adjustment of implantable device to test the function of device and to select optimal permanent programmed values, with analysis, review, and report, by a physician or other qualified health care professional, leadless pacemaker system in dual cardiac chambers | Investigational |
| 0805T | Transcatheter superior and inferior vena cava prosthetic valve implantation (i.e., caval valve implantation [CAVI]); percutaneous femoral vein approach | Investigational |
| 0806T | Transcatheter superior and inferior vena cava prosthetic valve implantation (i.e., caval valve implantation [CAVI]); open femoral vein approach | Investigational |

| | | |
|--------------|--|-----------------|
| 0807T | Pulmonary tissue ventilation analysis using software-based processing of data from separately captured cinefluorograph images; in combination with previously acquired computed tomography (CT) images, including data preparation and transmission, quantification of pulmonary tissue ventilation, data review, interpretation and report | Investigational |
| 0808T | Pulmonary tissue ventilation analysis using software-based processing of data from separately captured cinefluorograph images; in combination with computed tomography (CT) images taken for the purpose of pulmonary tissue ventilation analysis, including data preparation and transmission, quantification of pulmonary tissue ventilation, data review, interpretation and report | Investigational |
| 0809T | Arthrodesis, sacroiliac joint, percutaneous or minimally invasive (indirect visualization), with image guidance, placement of transfixing device(s) and intraarticular implant(s), including allograft or synthetic device(s) | Investigational |
| 20560 | Needle insertion(s) without injection(s); 1 or 2 muscle(s) | Investigational |
| 20561 | Needle insertion(s) without injection(s); 3 or more muscles | Investigational |
| 22526 | Percutaneous intradiscal electrothermal annuloplasty, unilateral or bilateral including fluoroscopic guidance; single level | Investigational |
| 22527 | Percutaneous intradiscal electrothermal annuloplasty, unilateral or bilateral including fluoroscopic guidance; 1 or more additional levels (List separately in addition to code for primary procedure) | Investigational |

| | | |
|--------------|---|-----------------|
| 22857 | Total disc arthroplasty (artificial disc), anterior approach, including discectomy to prepare interspace (other than for decompression), single interspace, lumbar | Investigational |
| 22860 | Total disc arthroplasty, anterior approach, including discectomy ; second lumbar interspace | Investigational |
| 22862 | Revision including replacement of total disc arthroplasty (artificial disc), anterior approach, single interspace; lumbar | Investigational |
| 22867 | Insertion of interlaminar/interspinous process stabilization/distraction device, without fusion, including image guidance when performed, with open decompression, lumbar; single level | Investigational |
| 22868 | Insertion of interlaminar/interspinous process stabilization/distraction device, without fusion, including image guidance when performed, with open decompression, lumbar; second level (List separately in addition to code for primary procedure) | Investigational |
| 22869 | Insertion of interlaminar/interspinous process stabilization/distraction device, without open decompression or fusion, including image guidance when performed, lumbar; single level | Investigational |
| 22870 | Insertion of interlaminar/interspinous process stabilization/distraction device, without open decompression or fusion, including image guidance when performed, lumbar; second level (List separately in addition to code for primary procedure) | Investigational |
| 28890 | Extracorporeal shock wave, high energy, performed by a physician or other qualified health care professional, requiring anesthesia other than local, including ultrasound guidance, involving the plantar fascia | Investigational |

| | | |
|--------------|---|-----------------|
| 30468 | Repair of nasal valve collapse with subcutaneous/submucosal lateral wall implant(s) | Investigational |
| 30469 | Nasal valve collapse repair using low energy, temperature-controlled remodeling | Investigational |
| 31647 | Bronchoscopy, rigid or flexible, including fluoroscopic guidance, when performed; with balloon occlusion, when performed, assessment of air leak, airway sizing, and insertion of bronchial valve(s), initial lobe | Investigational |
| 31648 | Bronchoscopy, rigid or flexible, including fluoroscopic guidance, when performed; with removal of bronchial valve(s), initial lobe | Investigational |
| 31649 | Bronchoscopy, rigid or flexible, including fluoroscopic guidance, when performed; with removal of bronchial valve(s), each additional lobe (List separately in addition to code for primary procedure) | Investigational |
| 31651 | Bronchoscopy, rigid or flexible, including fluoroscopic guidance, when performed; with balloon occlusion, when performed, assessment of air leak, airway sizing, and insertion of bronchial valve(s), each additional lobe (List separately in addition to code for primary procedure[s]) | Investigational |
| 31660 | Bronchoscopy, rigid or flexible, including fluoroscopic guidance, when performed; with bronchial thermoplasty, 1 lobe | Investigational |
| 31661 | Bronchoscopy, rigid or flexible, including fluoroscopic guidance, when performed; with bronchial thermoplasty, 2 or more lobes | Investigational |
| 33274 | Transcatheter insertion or replacement of permanent leadless pacemaker, right ventricular, including imaging guidance (eg, fluoroscopy, venous ultrasound, ventriculography, femoral venography) and device evaluation (eg, interrogation or programming), when performed | Investigational |

| | | |
|--------------|---|-----------------|
| 33275 | Transcatheter removal of permanent leadless pacemaker, right ventricular, including imaging guidance (eg, fluoroscopy, venous ultrasound, ventriculography, femoral venography), when performed | Investigational |
| 33289 | Transcatheter implantation of wireless pulmonary artery pressure sensor for long-term hemodynamic monitoring, including deployment and calibration of the sensor, right heart catheterization, selective pulmonary catheterization, radiological supervision and interpretation, and pulmonary artery angiography, when performed | Investigational |
| 33370 | Transcatheter placement and subsequent removal of cerebral embolic protection device(s), including arterial access, catheterization, imaging, and radiological supervision and interpretation, percutaneous (List separately in addition to code for primary procedure) | Investigational |
| 33548 | Surgical ventricular restoration procedure, includes prosthetic patch, when performed (eg, ventricular remodeling, SVR, SAVER, Dor procedures) | Investigational |
| 36836 | Upper extremity, single access percutaneous arteriovenous fistula creation | Investigational |
| 36837 | Upper extremity, separate access percutaneous arteriovenous fistula creation | Investigational |
| 41512 | Tongue base suspension, permanent suture technique | Investigational |
| 43206 | Esophagoscopy, flexible, transoral; with optical endomicroscopy | Investigational |
| 43252 | Esophagogastroduodenoscopy, flexible, transoral; with optical endomicroscopy | Investigational |
| 43284 | Laparoscopy, surgical, esophageal sphincter augmentation procedure, placement of sphincter augmentation device (ie, magnetic band), including cruroplasty when performed | Investigational |

| | | |
|--------------|---|-----------------|
| 43285 | Removal of esophageal sphincter augmentation device | Investigational |
| 43290 | Esophagogastroduodenoscopy, with deployment of balloon | Investigational |
| 43291 | Esophagogastroduodenoscopy, with removal of balloon | Investigational |
| 43497 | Lower esophageal myotomy, transoral (ie, peroral endoscopic myotomy [POEM]) | Investigational |
| 43647 | Laparoscopy, surgical; implantation or replacement of gastric neurostimulator electrodes, antrum | Investigational |
| 43648 | Laparoscopy, surgical; revision or removal of gastric neurostimulator electrodes, antrum | Investigational |
| 43881 | Implantation or replacement of gastric neurostimulator electrodes, antrum, open | Investigational |
| 43882 | Revision or removal of gastric neurostimulator electrodes, antrum, open | Investigational |
| 46707 | Repair of anorectal fistula with plug (eg, porcine small intestine submucosa [SIS]) | Investigational |
| 47371 | Laparoscopy, surgical, ablation of 1 or more liver tumor(s); cryosurgical | Investigational |
| 47381 | Ablation, open, of 1 or more liver tumor(s); cryosurgical | Investigational |
| 47383 | Ablation, 1 or more liver tumor(s), percutaneous, cryoablation | Investigational |
| 53451 | Periurethral transperineal adjustable balloon continence device; bilateral insertion, including cystourethroscopy and imaging guidance | Investigational |
| 53452 | Periurethral transperineal adjustable balloon continence device; unilateral insertion, including cystourethroscopy and imaging guidance | Investigational |
| 53453 | Periurethral transperineal adjustable balloon continence device; removal, each balloon | Investigational |
| 53454 | Periurethral transperineal adjustable balloon continence device; percutaneous adjustment of balloon(s) fluid volume | Investigational |

| | | |
|--------------|---|-----------------|
| 55706 | Biopsies, prostate, needle, transperineal, stereotactic template guided saturation sampling, including imaging guidance | Investigational |
| 55880 | Ablation of malignant prostate tissue, transrectal, with high intensity-focused ultrasound (HIFU), including ultrasound guidance | Investigational |
| 61736 | Laser interstitial thermal therapy (LITT) of lesion, intracranial, including burr hole(s), with magnetic resonance imaging guidance, when performed; single trajectory for 1 simple lesion | Investigational |
| 61737 | Laser interstitial thermal therapy (LITT) of lesion, intracranial, including burr hole(s), with magnetic resonance imaging guidance, when performed; multiple trajectories for multiple or complex lesion(s) | Investigational |
| 62263 | Percutaneous lysis of epidural adhesions using solution injection (eg, hypertonic saline, enzyme) or mechanical means (eg, catheter) including radiologic localization (includes contrast when administered), multiple adhesiolysis sessions; 2 or more days | Investigational |
| 62264 | Percutaneous lysis of epidural adhesions using solution injection (eg, hypertonic saline, enzyme) or mechanical means (eg, catheter) including radiologic localization (includes contrast when administered), multiple adhesiolysis sessions; 1 day | Investigational |
| 62287 | Decompression procedure, percutaneous, of nucleus pulposus of intervertebral disc, any method utilizing needle based technique to remove disc material under fluoroscopic imaging or other form of indirect visualization, with discography and/or epidural injection(s) at the treated level(s), when performed, single or multiple levels, lumbar | Investigational |

| | | |
|--------------|---|-----------------|
| 62380 | Endoscopic decompression of spinal cord, nerve root(s), including laminotomy, partial facetectomy, foraminotomy, discectomy and/or excision of herniated intervertebral disc, 1 interspace, lumbar | Investigational |
| 64454 | Injection(s), anesthetic agent(s) and/or steroid; genicular nerve branches, including imaging guidance, when performed | Investigational |
| 64505 | Injection, anesthetic agent; sphenopalatine ganglion | Investigational |
| 64575 | Open implantation of neurostimulator electrode array; peripheral nerve (excludes sacral nerve) | Investigational |
| 64585 | Revision or removal of peripheral neurostimulator electrode array | Investigational |
| 64624 | Destruction by neurolytic agent, genicular nerve branches including imaging guidance, when performed | Investigational |
| 64625 | Radiofrequency ablation, nerves innervating the sacroiliac joint, with image guidance (ie, fluoroscopy or computed tomography) | Investigational |
| 64628 | Thermal destruction of intraosseous basivertebral nerve, including all imaging guidance; first 2 vertebral bodies, lumbar or sacral | Investigational |
| 64629 | Thermal destruction of intraosseous basivertebral nerve, including all imaging guidance; each additional vertebral body, lumbar or sacral (List separately in addition to code for primary procedure) | Investigational |
| 76120 | Cineradiography/videoradiography, except where specifically included | Investigational |
| 76125 | Cineradiography/videoradiography to complement routine examination (List separately in addition to code for primary procedure) | Investigational |
| 77085 | Dual-energy X-ray absorptiometry (DXA), bone density study, 1 or more sites; axial skeleton (eg, hips, pelvis, spine), including vertebral fracture assessment | Investigational |

| | | |
|--------------|--|-----------------|
| 77086 | Vertebral fracture assessment via dual-energy X-ray absorptiometry (DXA) | Investigational |
| 77089 | Trabecular bone score (TBS), structural condition of the bone microarchitecture; using dual X-ray absorptiometry (DXA) or other imaging data on gray-scale variogram, calculation, with interpretation and report on fracture-risk | Investigational |
| 77090 | Trabecular bone score (TBS), structural condition of the bone microarchitecture; technical preparation and transmission of data for analysis to be performed elsewhere | Investigational |
| 77091 | Trabecular bone score (TBS), structural condition of the bone microarchitecture; technical calculation only | Investigational |
| 77092 | Trabecular bone score (TBS), structural condition of the bone microarchitecture; interpretation and report on fracture-risk only by other qualified health care professional | Investigational |
| 78835 | Radiopharmaceutical quantification measurement(s) single area (List separately in addition to code for primary procedure) | Investigational |
| 81277 | Cytogenomic neoplasia (genome-wide) microarray analysis, interrogation of genomic regions for copy number and loss-of-heterozygosity variants for chromosomal abnormalities | Investigational |
| 81418 | Drug metabolism genomic sequence panel, must include testing of at least 6 genes, including CYP2C19, CYP2D6, and CYP2D6 duplications and deletions | Investigational |
| 81449 | Targeted genomic sequence analysis panel, solid organ neoplasm, 5-50 genes RNA analysis | Investigational |

| | | |
|--------------|---|-----------------|
| 81451 | Targeted genomic sequence analysis panel, hematolymphoid neoplasm or disorder, 5-50 genes RNA analysis | Investigational |
| 81456 | Targeted genomic sequence analysis panel, solid organ or hematolymphoid neoplasm or disorder, 51 or greater genes RNA analysis | Investigational |
| 81514 | Infectious disease, bacterial vaginosis and vaginitis, quantitative real-time amplification of DNA markers for <i>Gardnerella vaginalis</i> , <i>Atopobium vaginae</i> , <i>Megasphaera</i> type 1, Bacterial Vaginosis Associated Bacteria-2 (BVAB-2), and <i>Lactobacillus</i> species (<i>L. crispatus</i> and <i>L. jensenii</i>), utilizing vaginal-fluid specimens, algorithm reported as a positive or negative for high likelihood of bacterial vaginosis, includes separate detection of <i>Trichomonas vaginalis</i> and/or <i>Candida</i> species (<i>C. albicans</i> , <i>C. tropicalis</i> , <i>C. parapsilosis</i> , <i>C. dubliniensis</i>), <i>Candida glabrata</i> , <i>Candida krusei</i> , when reported | Investigational |
| 81539 | Oncology (high-grade prostate cancer), biochemical assay of four proteins (Total PSA, Free PSA, Intact PSA, and human kallikrein-2 [hK2]), utilizing plasma or serum, prognostic algorithm reported as a probability score | Investigational |
| 81560 | Transplantation medicine (allograft rejection, pediatric liver and small bowel), measurement of donor and third party-induced CD154+T-cytotoxic memory cells, utilizing whole peripheral blood, algorithm reported as a rejection risk score | Investigational |
| 82107 | Alpha-fetoprotein (AFP); AFP-L3 fraction isoform and total AFP (including ratio) | Investigational |
| 82172 | Apolipoprotein, each | Investigational |
| 82523 | Collagen cross links, any method | Investigational |
| 82610 | Cystatin C | Investigational |
| 82664 | Electrophoretic technique, not elsewhere specified | Investigational |

| | | |
|--------------|--|---|
| 83006 | Growth stimulation expressed gene 2 (ST2, Interleukin 1 receptor like-1) | Investigational |
| 83695 | Lipoprotein (a) | Investigational |
| 83722 | Lipoprotein, direct measurement; small dense LDL cholesterol | Investigational |
| 83937 | Osteocalcin (bone g1a protein) | Investigational |
| 83987 | pH; exhaled breath condensate | Investigational |
| 84080 | Phosphatase, alkaline; isoenzymes | Investigational |
| 86305 | Human epididymis protein 4 (HE4) | Investigational |
| 86352 | Cellular function assay involving stimulation (eg, mitogen or antigen) and detection of biomarker (eg, ATP) | Investigational |
| 88375 | Optical endomicroscopic image(s), interpretation and report, real-time or referred, each endoscopic session | Investigational |
| 90584 | Dengue vaccine, quadrivalent, live, 2 dose schedule, for subcutaneous use | Investigational |
| 91111 | Gastrointestinal tract imaging, intraluminal (eg, capsule endoscopy), esophagus with interpretation and report | Investigational |
| 91300 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted, for intramuscular use | Investigational COVID-19 Effective:(04/18/2023) |
| 91301 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage, for intramuscular use | Investigational COVID-19 Effective:(04/18/2023) |
| 91303 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x10 ¹⁰ viral particles/0.5mL dosage, for intramuscular use | Investigational COVID-19 Effective:(05/07/2023) |

| | | |
|--------------|---|---|
| 91305 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use | Investigational COVID-19 Effective:(04/18/2023) |
| 91306 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.25 mL dosage, for intramuscular use | Investigational COVID-19 Effective:(04/18/2023) |
| 91307 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use | Investigational COVID-19 Effective:(04/18/2023) |
| 91308 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use | Investigational COVID-19 Effective:(04/18/2023) |
| 91309 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.5 mL dosage, for intramuscular use | Investigational COVID-19 Effective:(04/18/2023) |
| 91311 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 25 mcg/0.25 mL dosage, for intramuscular use | Investigational COVID-19 Effective:(04/18/2023) |
| 92145 | Corneal hysteresis determination, by air impulse stimulation, unilateral or bilateral, with interpretation and report | Investigational |

| | | |
|--------------|---|-----------------|
| 92548 | Computerized dynamic posturography sensory organization test (CDP-SOT), 6 conditions (ie, eyes open, eyes closed, visual sway, platform sway, eyes closed platform sway, platform and visual sway), including interpretation and report; | Investigational |
| 92549 | Computerized dynamic posturography sensory organization test (CDP-SOT), 6 conditions (ie, eyes open, eyes closed, visual sway, platform sway, eyes closed platform sway, platform and visual sway), including interpretation and report; with motor control test (MCT) and adaptation test (ADT) | Investigational |
| 92572 | Staggered spondaic word test | Investigational |
| 92576 | Synthetic sentence identification test | Investigational |
| 93050 | Arterial pressure waveform analysis for assessment of central arterial pressures, includes obtaining waveform(s), digitization and application of nonlinear mathematical transformations to determine central arterial pressures and augmentation index, with interpretation and report, upper extremity artery, non-invasive | Investigational |
| 93264 | Remote monitoring of a wireless pulmonary artery pressure sensor for up to 30 days, including at least weekly downloads of pulmonary artery pressure recordings, interpretation(s), trend analysis, and report(s) by a physician or other qualified health care professional | Investigational |
| 93356 | Myocardial strain imaging using speckle tracking-derived assessment of myocardial mechanics (List separately in addition to codes for echocardiography imaging) | Investigational |
| 93701 | Bioimpedance-derived physiologic cardiovascular analysis | Investigational |

| | | |
|--------------|--|-----------------|
| 95012 | Nitric oxide expired gas determination | Investigational |
| 95803 | Actigraphy testing, recording, analysis, interpretation, and report (minimum of 72 hours to 14 consecutive days of recording) | Investigational |
| 95905 | Motor and/or sensory nerve conduction, using preconfigured electrode array(s), amplitude and latency/velocity study, each limb, includes F-wave study when performed, with interpretation and report | Investigational |
| 95957 | Digital analysis of electroencephalogram (EEG) (eg, for epileptic spike analysis) | Investigational |
| 96000 | Comprehensive computer-based motion analysis by videotaping and 3D kinematics; | Investigational |
| 96001 | Comprehensive computer-based motion analysis by videotaping and 3D kinematics; with dynamic plantar pressure measurements during walking | Investigational |
| 96002 | Dynamic surface electromyography, during walking or other functional activities, 1-12 muscles | Investigational |
| 96003 | Dynamic fine wire electromyography, during walking or other functional activities, 1 muscle | Investigational |
| 96004 | Review and interpretation by physician or other qualified health care professional of comprehensive computer-based motion analysis, dynamic plantar pressure measurements, dynamic surface electromyography during walking or other functional activities, and dynamic fine wire electromyography, with written report | Investigational |
| 97033 | Application of a modality to 1 or more areas; iontophoresis, each 15 minutes | Investigational |

| | | |
|--------------|--|-----------------|
| 97533 | Sensory integrative techniques to enhance sensory processing and promote adaptive responses to environmental demands, direct (one-on-one) patient contact, each 15 minutes | Investigational |
| 97610 | Low frequency, non-contact, non-thermal ultrasound, including topical application(s), when performed, wound assessment, and instruction(s) for ongoing care, per day | Investigational |
| 97799 | Unlisted physical medicine/rehabilitation service or procedure | Investigational |
| 98978 | Remote therapeutic monitoring; device supply, recording, transmission to monitor cognitive behavioral therapy, each 30 days | Investigational |
| | | |